<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02446743</url>
  </required_header>
  <id_info>
    <org_study_id>205218</org_study_id>
    <secondary_id>V72_75</secondary_id>
    <secondary_id>2017-000093-11</secondary_id>
    <nct_id>NCT02446743</nct_id>
  </id_info>
  <brief_title>Combined Study - Phase 3b MenB Long Term Persistence in Adolescents</brief_title>
  <official_title>A Phase 3b, Open Label, Controlled, Multi-Center, Extension Study to Assess the Persistence of Bactericidal Activity at 4 to 7.5 Years After Two Dose Primary Series of GlaxoSmithKline Biologicals Meningococcal B Recombinant Vaccine and the Response to a Third Dose in Adolescents and Young Adult Subjects Who Previously Participated in Parent Studies V72_41 (NCT01423084) and V72P10 (NCT00661713), Compared to Naïve Healthy Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose/aim of this study is to assess 1) the long-term persistence (4 to 7.5 years after
      the last dose) of bactericidal activity following primary vaccination with rMenB+OMV NZ in
      adolescents [who previously participated in parent studies V72_41 (NCT0142384) and V72P10
      (NCT00661713)] and 2) the kinetics of immune response following booster vaccination with
      rMenB+OMV NZ
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After all subjects (Groups A and B) from Canada and Australia have completed the study, an
      interim analysis for the primary and secondary immunogenicity objectives will be performed.
      Follow on subjects (Group A) from parent study V72_41 (NCT0142384) will be analyzed for i)
      antibody persistence at approximately 4 years following a 2 dose primary series and ii) the
      immune response at 3, 7 and 30 days after a third dose (booster) of rMenB+OMV NZ. Canadian
      and Australian vaccine naïve subjects (Group B) will be analyzed for the immune response at
      30 days after the first dose, and 3, 7 and 30 days after the second dose of rMenB+OMV NZ.

      Subjects in Group B (naïve subjects) will be randomized into two different blood draw
      schedules according to a 1:1 ratio.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 17, 2015</start_date>
  <completion_date type="Actual">September 23, 2016</completion_date>
  <primary_completion_date type="Actual">September 23, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Human Serum Bactericidal Activity (hSBA) ≥1:5</measure>
    <time_frame>Group 3B: Day 1 (prior to booster dose); Group B_0_1: Day 1 (prior to first dose).</time_frame>
    <description>Bactericidal activity was measured against each of the N. meningitidis group B indicator strains H44/76, 5/99, NZ98/254 a nd M10713</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With hSBA≥1:8</measure>
    <time_frame>Group 3B: Day 1 (prior to booster dose); Group B_0_1: Day 1 (prior to first dose).</time_frame>
    <description>Bactericidal activity was measured against each of the N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With hSBA≥1:16</measure>
    <time_frame>Group 3B: Day 1 (prior to booster dose); Group B_0_1: Day 1 (prior to first dose).</time_frame>
    <description>Bactericidal activity was measured against each of the N. meningitidis group B Indicator strains H44/76,5/99,NZ98/254 and M10713</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hSBA Geometric Mean Titers (GMTs) After the Last Dose of rMenB+OMV NZ Vaccination in the Parent Study.</measure>
    <time_frame>Group 3B: 1 month after the last rMenB+OMV NZ vaccination in parent study and Day 1(prior to booster dose); Group B_0_1: Day 1(prior to first dose)</time_frame>
    <description>Bactericidal activity was measured against each of the N. meningitidis group B indicator strains H44/76,5/99, NZ98/254 a nd M10713.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratios (GMRs) of GMTs After the Last Dose of rMenB+OMV NZ Vaccination in the Parent Study Versus Day 1.</measure>
    <time_frame>Group 3B: 1 month after the last vaccination in parent study and Day 1 (prior to booster dose)</time_frame>
    <description>The GMRs of GMTs at Day 1 versus one month after the last dose of rMenB+OMV NZ vaccination in the parent study were calculated. Bactericidal activity was measured against each of the N. meningitidis group B indicator strains H44/76, 5/99,NZ98/254 and M10713.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Solicited Local and Systemic AEs.</measure>
    <time_frame>7 days (including the day of vaccination) after each vaccination</time_frame>
    <description>Solicited adverse events are signs and symptoms derived from organized data collection systems, such as Subject Diaries or interview. The percentage and frequencies of subjects reporting solicited local and systemic AEs were tabulated. Threshold for any Erythema, Swelling and Induration: &gt;= 25 mm Note:Vaccination 2 was performed only on group B_0_1 subjects. Threshold for any Erythema, Swelling and Induration: &gt;= 25 mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any Unsolicited Adverse Events (AEs).</measure>
    <time_frame>30 days (including the day of vaccination) after each vaccination.</time_frame>
    <description>An unsolicited adverse event is an adverse event that was not solicited using a subject Diary and that was spontaneously communicated by a subject and/or parent(s)/legal guardian(s) who has signed the informed consent. Note : Vaccination 2 was performed only on group B_0_1 subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any SAEs, AEs Leading to Withdrawal and Medically Attended AEs.</measure>
    <time_frame>Group 3B: from Day 1 to Day 31 (study termination visit) and Group B_0_1: from Day 1 to Day 61 (study termination visit)</time_frame>
    <description>A serious adverse event is any untoward medical occurrence that at any dose results in death or is life threatening or requires prolonged hospitalization, leads to Persistent or significant disability/incapacity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA ≥1:5 After Booster Dose/First Vaccination of rMenB+OMV NZ.</measure>
    <time_frame>Group 3B: 30 days after booster dose, Group B_0_1 : 30 days after first vaccination.</time_frame>
    <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA ≥1:8 After Booster Dose/First Vaccination of rMenB+OMV NZ</measure>
    <time_frame>Group 3B : 30 days after booster dose, Group B_0_1 : 30 days after first vaccination.</time_frame>
    <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA ≥1:16 After Booster Dose/First Vaccination of rMenB+OMV NZ</measure>
    <time_frame>Group 3B: 30 days after booster dose, Group B_0_1 : 30 days after first vaccination.</time_frame>
    <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76, 5/99, NZ98/254 &amp; M10713.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA Geometric Mean Titers Prior to Booster/First Dose of Vaccination &amp; Post Booster/First Dose of Vaccination.</measure>
    <time_frame>Group 3B subjects: Day 1(pre-booster dose) and 30 days post-booster dose. Group B_0_1: Day 1 (pre-first dose) and 30 days post-first dose.</time_frame>
    <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76, 5/99,NZ98/254 and M10713.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio (GMRs) of GMTs After Booster Dose/First rMenB+OMV NZ Vaccination Versus Day 1.</measure>
    <time_frame>At Day 31 (30 days post booster dose/first dose of vaccination) versus Day 1 (prior to booster dose/first dose of vaccination).</time_frame>
    <description>Bactericidal activity was measured against each of the fout N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713 by calculating the GMRs of GMTs one month post-vaccination of a booster dose versus pre-booster dose (follow-on subjects) or first dose of rMenB+OMV NZ versus prefirst dose (naïve subjects) to each N. meningitidis group B indicator strain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With at Least 4-fold Increase in hSBA Titers Pre Vaccination Compared to One Month Post-booster/First rMenB+OMV NZ Vaccination</measure>
    <time_frame>Group 3B: 1 month after booster dose; Group B_0_1: 1 month after first vaccination</time_frame>
    <description>The percentage of subjects with 4-fold rise at one month post-vaccination with a booster dose (follow-on subjects) /first dose (naive subjects) of rMenB+OMV NZ with respect to day 1 (follow-on subjects) / pre-first dose of rMenB+OMV NZ (naïve subjects). Percentage of subjects with four-fold rise in hSBA titers relative to baseline were defined as: • for a pre-vaccination titer &lt; 4, a post-vaccination titer of at least 16; • for a pre-vaccination titer ≥ 4 but &lt;LLOQ, a post vaccination titer of at least fourfold the LLOQ; • for a pre-vaccination titer ≥LLOQ, a post vaccination titer of at least fourfold the pre-vaccination titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA ≥1:5 After Booster Dose/Second Vaccination of rMenB+OMV NZ</measure>
    <time_frame>Group 3B: 3, 7 and 30 days after third dose booster; Group B_0_1: At 3 (group B_0_1_1 only), 7 (sub-group B_0_1_2 only) and 30 days post-second dose.&quot;</time_frame>
    <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713. On day 1, subjects in the Group B_0_1 were to be randomized into 2 different blood draw schedules according to a 1:1 ratio : 2 blood samples at different time points:
Group B_0_1_1: blood draws at 3 and 30 days after the second dose. Group B_0_1_2: blood draws at 7 and 30 days after the second dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA ≥1:8 After Booster Dose/Second Vaccination of rMenB+OMV NZ</measure>
    <time_frame>Group 3B: 3, 7 and 30 days after third dose booster; Group B_0_1: At 3 (group B_0_1_1 only), 7 (sub-group B_0_1_2 only) and 30 days post-second dose.</time_frame>
    <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713. On day 1, subjects in the Group B_0_1 were to be randomized into 2 different blood draw schedules according to a 1:1 ratio : 2 blood samples at different time points:
Group B_0_1_1: blood draws at 3 and 30 days after the second dose. Group B_0_1_2: blood draws at 7 and 30 days after the second dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA ≥1:16 After Booster Dose/Second Vaccination of rMenB+OMV NZ</measure>
    <time_frame>Group 3B: 3, 7 and 30 days after third dose booster; Group B_0_1: At 3 (group B_0_1_1 only), 7 (sub-group B_0_1_2 only) and 30 days post-second dose</time_frame>
    <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713. On day 1, subjects in the Group B_0_1 were to be randomized into 2 different blood draw schedules according to a 1:1 ratio : 2 blood samples at different time points:
Group B_0_1_1: blood draws at 3 and 30 days after the second dose. Group B_0_1_2: blood draws at 7 and 30 days after the second dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA Geometric Mean Titers Prior to Booster/Second Dose of Vaccination &amp; Post Booster/Second Dose of Vaccination.</measure>
    <time_frame>Group 3B: Day 1 (pre-booster dose) and 3, 7 and 30 days after third dose booster; Group B_0_1: Pre 2nd dose and at 3 (group B_0_1_1 only), 7 (group B_0_1_2 only) and 30 days post second dose.</time_frame>
    <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713. On day 1, subjects in the Group B_0_1 were to be randomized into 2 different blood draw schedules according to a 1:1 ratio : 2 blood samples at different time points:
Group B_0_1_1: blood draws at 3 and 30 days after the second dose. Group B_0_1_2: blood draws at 7 and 30 days after the second dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratios (GMRs) of GMTs After Booster/Second Vaccination Versus Before Booster/Second Vaccination.</measure>
    <time_frame>Group 3B: Day 1 and 30 days after third dose booster; Group B_0_1: 30 days post-first dose and at 30 days post-second dose</time_frame>
    <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713 by calculating the GMRs of GMTs post-vaccination with a booster dose (Group 3B) versus pre-booster dose or second dose (Group B_0_1) of vaccination versus pre second dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With at Least Four-fold Increase in hSBA Titers Pre-booster/Second Dose Vaccination- Compared to 3, 7 and 30 Days Post- Booster/Second Vaccination</measure>
    <time_frame>Group 3B: at 3, 7 and 30 days after third dose booster; Group B_0_1: at 3 (group B_0_1_1 only), 7 (group B_0_1_2 only) and 30 days post second dose</time_frame>
    <description>The percentage of subjects with 4-fold rise at 3, 7, 30 days post-vaccination with a booster dose (follow-on subjects) /second dose (naive subjects) of rMenB+OMV NZ with respect to day 1 (follow-on subjects) / pre-second dose of rMenB+OMV NZ (naïve subjects). Percentage of subjects with four-fold rise in hSBA titers relative to baseline were defined as: • for a pre-vaccination titer &lt; 4, a post-vaccination titer of at least 16; • for a pre-vaccination titer ≥ 4 but &lt;LLOQ, a post vaccination titer of at least fourfold the LLOQ; • for a pre-vaccination titer ≥LLOQ, a post vaccination titer of at least fourfold the pre-vaccination titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA ≥1:5 After Second Vaccination of rMenB+OMV NZ</measure>
    <time_frame>At Day 61 (30 days post second dose of vaccination.)</time_frame>
    <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713. Only subjects receiving a second vaccination (group B_0_1) were assessed for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA ≥1:8 After Second Vaccination of rMenB+OMV NZ.</measure>
    <time_frame>At Day 61 (30 days post second vaccination)</time_frame>
    <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.
Only subjects receiving a second vaccination (group B_0_1) were assessed for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA ≥1:16 After Second Vaccination of rMenB+OMV NZ.</measure>
    <time_frame>At Day 61 (30 days post second vaccination)</time_frame>
    <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.
Only subjects receiving a second vaccination (group B_0_1) were assessed for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA Geometric Mean Titers (GMTs) After Second Vaccination of rMenB+OMV NZ.</measure>
    <time_frame>At Day 1 &amp; Day 61 (30 days post second dose of vaccination)</time_frame>
    <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.
Only subjects receiving a second vaccination (group B_0_1) were assessed for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio (GMRs) of GMTs One Month Post Second Vaccination Versus Pre Vaccination at Day 1</measure>
    <time_frame>At Day 1 &amp; Day 61 (30 days post 2nd vaccination)</time_frame>
    <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.
Only subjects receiving a second vaccination (group B_0_1) were assessed for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With at Least Four-fold Increase in hSBA Titers at Pre-First Vaccination Compared to One Month Post-Second Vaccination</measure>
    <time_frame>At Day 61 (30 days post second dose of vaccination)</time_frame>
    <description>The percentage of subjects with 4-fold rise at one month post-vaccination with a second dose (naïve subjects) of rMenB+OMV NZ with respect to day 1, to each and any one, two, three or all 4 indicator strains.
Percentage of subjects with four-fold rise in hSBA titers relative to baseline were defined as:
for a pre-vaccination titer &lt; 4, a post-vaccination titer of at least 16;
for a pre-vaccination titer ≥ 4 but &lt;LLOQ, a post vaccination titer of at least fourfold the LLOQ;
for a pre-vaccination titer ≥LLOQ, a post vaccination titer of at least fourfold the pre-vaccination titer.
Only subjects receiving the second dose of vaccination(group B_0_1) were considered for this outcome measure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">531</enrollment>
  <condition>Infections, Meningococcal</condition>
  <arm_group>
    <arm_group_label>Group 3B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during studies V72P10 (NCT00661713) or V72_41(NCT0142384), and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B_0_1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)</intervention_name>
    <description>One dose of the vaccine administered intramuscularly in the deltoid area of the non-dominant arm.</description>
    <arm_group_label>Group 3B</arm_group_label>
    <arm_group_label>Group B_0_1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion Criterion for follow-on subjects:

          -  Individuals who participated to Study V72_41 or V72P10 and have completed vaccination
             with rMenB+OMV NZ according to a 2-dose schedule

        Inclusion Criterion for naïve subjects:

          -  Individuals of 15 through 21 years of age on the day of informed consent and assent as
             applicable (according to the subject's age) for subjects enrolled at sites that
             participated to Study V72_41.

          -  17 through 24 years of age on the day of informed consent and assent as applicable
             (according to the subject's age) for subjects enrolled at sites that participated to
             Study V72P10.

        Inclusion Criteria for all subjects:

          -  Individuals who have voluntarily given written informed consent after the nature of
             the study has been explained according to local regulatory requirements, prior to
             study entry.

          -  Individuals who can comply with study procedures including follow-up.

          -  Males Or Females of non-childbearing potential Or Females of childbearing potential
             who are using an effective birth control method .

        Exclusion Criteria for all subjects

        Exclusion Criterion for follow-on subjects:

        • Received a third dose of a Meningococcal group B vaccine prior to enrolment in this
        study.

        Exclusion Criterion for naïve subjects:

        • Received any other Meningococcal group B vaccines prior to enrolment in this study.

        Exclusion Criteria for all subjects:

          -  Progressive, unstable or uncontrolled clinical conditions.

          -  Hypersensitivity, including allergy, to any component of vaccines or medical equipment
             whose use is foreseen in this study.

          -  Abnormal function of the immune system.

          -  Received immunoglobulins or any blood products within 180 days prior to informed
             consent and assent as applicable (according to the subject's age).

          -  Received an investigational or non-registered medicinal product within 30 days prior
             to informed consent and assent as applicable (according to the subject's age).

          -  Study personnel as an immediate family or household member.

          -  Any other clinical condition that, in the opinion of the investigator, might pose
             additional risk to the subject due to participation in the study.

          -  Positive results at the urine pregnancy test performed before study vaccination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherwood</city>
        <state>Queensland</state>
        <zip>4075</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E1H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Woodstock</city>
        <state>Ontario</state>
        <zip>N4S5P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <zip>7500092</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <zip>8380453</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2015</study_first_posted>
  <results_first_submitted>September 19, 2017</results_first_submitted>
  <results_first_submitted_qc>November 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 13, 2017</results_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Meningitis</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 4 sites in Australia,6 sites in Canada &amp; 2 sites in Chile.Analysis were performed on the study population (Groups 3B and B_0_1), but also repeated &amp; stratified by parent study (i.e., V72_41 subjects using naïve subjects in Australia and Canada as controls, and V72P10 subjects using naïve subjects in Chile as controls)</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the study. Only groups 3B &amp; B_0_1 were accounted for enrollment number as subjects from parent studies are included in the group 3B.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 3B</title>
          <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 and at 0,1 month schedule in study V72_41, and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
        </group>
        <group group_id="P2">
          <title>Group B_0_1</title>
          <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="276"/>
                <participants group_id="P2" count="255"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="271"/>
                <participants group_id="P2" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 3B</title>
          <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 and at 0,1 month schedule in study V72_41, and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
        </group>
        <group group_id="B2">
          <title>Group B_0_1</title>
          <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="276"/>
            <count group_id="B2" value="255"/>
            <count group_id="B3" value="531"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.5" spread="2.42"/>
                    <measurement group_id="B2" value="20.0" spread="2.69"/>
                    <measurement group_id="B3" value="19.7" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="261"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethinicity</title>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="172"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Human Serum Bactericidal Activity (hSBA) ≥1:5</title>
        <description>Bactericidal activity was measured against each of the N. meningitidis group B indicator strains H44/76, 5/99, NZ98/254 a nd M10713</description>
        <time_frame>Group 3B: Day 1 (prior to booster dose); Group B_0_1: Day 1 (prior to first dose).</time_frame>
        <population>Analysis was performed on the Full analysis set (FAS) persistence. The FAS included all follow-on subjects (Group 3B) in the All Enrolled Set, and all naïve subjects (group B_0_1) in the All Enrolled Set who provided evaluable immunogenicity result at day 1, for at least one indicator strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B (V72_41)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1-month schedule in study V72_41 (NCT0142384) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72_41, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group 3B (V72P10)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72P10, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O3">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O4">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O5">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O6">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Human Serum Bactericidal Activity (hSBA) ≥1:5</title>
          <description>Bactericidal activity was measured against each of the N. meningitidis group B indicator strains H44/76, 5/99, NZ98/254 a nd M10713</description>
          <population>Analysis was performed on the Full analysis set (FAS) persistence. The FAS included all follow-on subjects (Group 3B) in the All Enrolled Set, and all naïve subjects (group B_0_1) in the All Enrolled Set who provided evaluable immunogenicity result at day 1, for at least one indicator strain.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="275"/>
                <count group_id="O4" value="105"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="275"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="150"/>
                    <count group_id="O6" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="19.4" upper_limit="34.4"/>
                    <measurement group_id="O2" value="41" lower_limit="32.7" upper_limit="50.2"/>
                    <measurement group_id="O3" value="33" lower_limit="27.9" upper_limit="39.4"/>
                    <measurement group_id="O4" value="5" lower_limit="1.6" upper_limit="10.8"/>
                    <measurement group_id="O5" value="11" lower_limit="6.7" upper_limit="17.5"/>
                    <measurement group_id="O6" value="9" lower_limit="5.5" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="254"/>
                    <count group_id="O4" value="100"/>
                    <count group_id="O5" value="139"/>
                    <count group_id="O6" value="239"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="76.2" upper_limit="89.4"/>
                    <measurement group_id="O2" value="84" lower_limit="76.4" upper_limit="90.2"/>
                    <measurement group_id="O3" value="84" lower_limit="78.7" upper_limit="88.2"/>
                    <measurement group_id="O4" value="5" lower_limit="1.6" upper_limit="11.3"/>
                    <measurement group_id="O5" value="22" lower_limit="15.1" upper_limit="29.4"/>
                    <measurement group_id="O6" value="15" lower_limit="10.4" upper_limit="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="129"/>
                    <count group_id="O3" value="273"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="148"/>
                    <count group_id="O6" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="4.9" upper_limit="14.9"/>
                    <measurement group_id="O2" value="27" lower_limit="19.7" upper_limit="35.7"/>
                    <measurement group_id="O3" value="18" lower_limit="13.3" upper_limit="22.6"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="14" lower_limit="9.0" upper_limit="20.9"/>
                    <measurement group_id="O6" value="8" lower_limit="5.2" upper_limit="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="274"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="150"/>
                    <count group_id="O6" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="63.2" upper_limit="78.6"/>
                    <measurement group_id="O2" value="78" lower_limit="69.8" upper_limit="84.6"/>
                    <measurement group_id="O3" value="74" lower_limit="68.9" upper_limit="79.5"/>
                    <measurement group_id="O4" value="59" lower_limit="49.0" upper_limit="68.5"/>
                    <measurement group_id="O5" value="78" lower_limit="70.5" upper_limit="84.3"/>
                    <measurement group_id="O6" value="70" lower_limit="64.2" upper_limit="75.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain H44/76and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.2</ci_lower_limit>
            <ci_upper_limit>31.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [(Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine groups difference</param_type>
            <param_value>22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.2</ci_lower_limit>
            <ci_upper_limit>30.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.0</ci_lower_limit>
            <ci_upper_limit>39.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>62.3</ci_lower_limit>
            <ci_upper_limit>75.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72_41)vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>69.7</ci_lower_limit>
            <ci_upper_limit>85.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>52.2</ci_lower_limit>
            <ci_upper_limit>71.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.6</ci_lower_limit>
            <ci_upper_limit>15.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.3</ci_lower_limit>
            <ci_upper_limit>14.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72P10 vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.5</ci_lower_limit>
            <ci_upper_limit>22.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>11.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72_41) vs. Group B_0_1(V72_41)]</non_inferiority_desc>
            <param_type>vaccine group differences</param_type>
            <param_value>12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>24.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72P10) vs. Group B_0_1(V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With hSBA≥1:8</title>
        <description>Bactericidal activity was measured against each of the N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713</description>
        <time_frame>Group 3B: Day 1 (prior to booster dose); Group B_0_1: Day 1 (prior to first dose).</time_frame>
        <population>Analysis was performed on the Full analysis set (FAS) persistence. The FAS included all follow-on subjects (Group 3B) in the All Enrolled Set, and all naïve subjects (group B_0_1) in the All Enrolled Set who provided evaluable immunogenicity result at day 1, for at least one indicator strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B (V72_41)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1-month schedule in study V72_41 (NCT0142384) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72_41, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group 3B (V72P10)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72P10, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O3">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O4">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O5">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O6">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA≥1:8</title>
          <description>Bactericidal activity was measured against each of the N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713</description>
          <population>Analysis was performed on the Full analysis set (FAS) persistence. The FAS included all follow-on subjects (Group 3B) in the All Enrolled Set, and all naïve subjects (group B_0_1) in the All Enrolled Set who provided evaluable immunogenicity result at day 1, for at least one indicator strain.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="275"/>
                <count group_id="O4" value="105"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="275"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="150"/>
                    <count group_id="O6" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="15.7" upper_limit="29.9"/>
                    <measurement group_id="O2" value="35" lower_limit="27.0" upper_limit="43.9"/>
                    <measurement group_id="O3" value="28" lower_limit="23.1" upper_limit="34.1"/>
                    <measurement group_id="O4" value="1" lower_limit="0.02" upper_limit="5.2"/>
                    <measurement group_id="O5" value="9" lower_limit="5.2" upper_limit="15.2"/>
                    <measurement group_id="O6" value="6" lower_limit="3.3" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="254"/>
                    <count group_id="O4" value="100"/>
                    <count group_id="O5" value="139"/>
                    <count group_id="O6" value="239"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="70.4" upper_limit="85.0"/>
                    <measurement group_id="O2" value="83" lower_limit="75.4" upper_limit="89.5"/>
                    <measurement group_id="O3" value="81" lower_limit="75.3" upper_limit="85.4"/>
                    <measurement group_id="O4" value="4" lower_limit="1.1" upper_limit="9.9"/>
                    <measurement group_id="O5" value="19" lower_limit="13.2" upper_limit="27.0"/>
                    <measurement group_id="O6" value="13" lower_limit="9.0" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="129"/>
                    <count group_id="O3" value="273"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="148"/>
                    <count group_id="O6" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="3.4" upper_limit="12.4"/>
                    <measurement group_id="O2" value="22" lower_limit="15.6" upper_limit="30.7"/>
                    <measurement group_id="O3" value="14" lower_limit="10.4" upper_limit="19.0"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="9" lower_limit="5.3" upper_limit="15.4"/>
                    <measurement group_id="O6" value="6" lower_limit="3.1" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="274"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="150"/>
                    <count group_id="O6" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="53.0" upper_limit="69.5"/>
                    <measurement group_id="O2" value="75" lower_limit="66.5" upper_limit="82.0"/>
                    <measurement group_id="O3" value="68" lower_limit="62.0" upper_limit="73.4"/>
                    <measurement group_id="O4" value="52" lower_limit="42.4" upper_limit="62.2"/>
                    <measurement group_id="O5" value="71" lower_limit="62.7" upper_limit="77.8"/>
                    <measurement group_id="O6" value="63" lower_limit="56.9" upper_limit="69.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.5</ci_lower_limit>
            <ci_upper_limit>28.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.6</ci_lower_limit>
            <ci_upper_limit>28.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain H44/76and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.4</ci_lower_limit>
            <ci_upper_limit>35.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>60.8</ci_lower_limit>
            <ci_upper_limit>73.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>65.3</ci_lower_limit>
            <ci_upper_limit>81.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>53.6</ci_lower_limit>
            <ci_upper_limit>72.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.7</ci_lower_limit>
            <ci_upper_limit>14.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.3</ci_lower_limit>
            <ci_upper_limit>12.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.5</ci_lower_limit>
            <ci_upper_limit>22.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>12.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>21.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis group B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4</ci_lower_limit>
            <ci_upper_limit>14.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With hSBA≥1:16</title>
        <description>Bactericidal activity was measured against each of the N. meningitidis group B Indicator strains H44/76,5/99,NZ98/254 and M10713</description>
        <time_frame>Group 3B: Day 1 (prior to booster dose); Group B_0_1: Day 1 (prior to first dose).</time_frame>
        <population>Analysis was performed on the Full analysis set (FAS) persistence. The FAS included all follow-on subjects (Group 3B) in the All Enrolled Set, and all naïve subjects in the All Enrolled Set who provided evaluable immunogenicity result at day 1, for at least one indicator strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B (V72_41)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1-month schedule in study V72_41 (NCT0142384) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72_41, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group 3B (V72P10)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72P10, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O3">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O4">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O5">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O6">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA≥1:16</title>
          <description>Bactericidal activity was measured against each of the N. meningitidis group B Indicator strains H44/76,5/99,NZ98/254 and M10713</description>
          <population>Analysis was performed on the Full analysis set (FAS) persistence. The FAS included all follow-on subjects (Group 3B) in the All Enrolled Set, and all naïve subjects in the All Enrolled Set who provided evaluable immunogenicity result at day 1, for at least one indicator strain.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="275"/>
                <count group_id="O4" value="105"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="275"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="150"/>
                    <count group_id="O6" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="7.0" upper_limit="18.2"/>
                    <measurement group_id="O2" value="28" lower_limit="20.7" upper_limit="36.8"/>
                    <measurement group_id="O3" value="20" lower_limit="15.1" upper_limit="24.8"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="7" lower_limit="3.7" upper_limit="12.7"/>
                    <measurement group_id="O6" value="4" lower_limit="2.2" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="254"/>
                    <count group_id="O4" value="100"/>
                    <count group_id="O5" value="139"/>
                    <count group_id="O6" value="239"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="63.2" upper_limit="79.1"/>
                    <measurement group_id="O2" value="78" lower_limit="69.9" upper_limit="85.3"/>
                    <measurement group_id="O3" value="75" lower_limit="69.0" upper_limit="80.0"/>
                    <measurement group_id="O4" value="2" lower_limit="0.24" upper_limit="7.0"/>
                    <measurement group_id="O5" value="13" lower_limit="7.9" upper_limit="19.7"/>
                    <measurement group_id="O6" value="8" lower_limit="5.2" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="129"/>
                    <count group_id="O3" value="273"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="148"/>
                    <count group_id="O6" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2.0" upper_limit="9.8"/>
                    <measurement group_id="O2" value="19" lower_limit="12.3" upper_limit="26.4"/>
                    <measurement group_id="O3" value="11" lower_limit="7.8" upper_limit="15.7"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="4" lower_limit="1.5" upper_limit="8.6"/>
                    <measurement group_id="O6" value="2" lower_limit="0.9" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="274"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="150"/>
                    <count group_id="O6" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="41.9" upper_limit="58.8"/>
                    <measurement group_id="O2" value="65" lower_limit="56.1" upper_limit="73.0"/>
                    <measurement group_id="O3" value="57" lower_limit="51.2" upper_limit="63.2"/>
                    <measurement group_id="O4" value="48" lower_limit="37.8" upper_limit="57.6"/>
                    <measurement group_id="O5" value="61" lower_limit="53.0" upper_limit="69.2"/>
                    <measurement group_id="O6" value="56" lower_limit="49.4" upper_limit="61.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.1</ci_lower_limit>
            <ci_upper_limit>20.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.5</ci_lower_limit>
            <ci_upper_limit>18.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.3</ci_lower_limit>
            <ci_upper_limit>29.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>59.6</ci_lower_limit>
            <ci_upper_limit>72.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>60.8</ci_lower_limit>
            <ci_upper_limit>77.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>55.2</ci_lower_limit>
            <ci_upper_limit>73.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.9</ci_lower_limit>
            <ci_upper_limit>13.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>9.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.5</ci_lower_limit>
            <ci_upper_limit>22.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.8</ci_lower_limit>
            <ci_upper_limit>15.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Persistence at 4/7.5 years/Baseline in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.8</ci_lower_limit>
            <ci_upper_limit>14.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>hSBA Geometric Mean Titers (GMTs) After the Last Dose of rMenB+OMV NZ Vaccination in the Parent Study.</title>
        <description>Bactericidal activity was measured against each of the N. meningitidis group B indicator strains H44/76,5/99, NZ98/254 a nd M10713.</description>
        <time_frame>Group 3B: 1 month after the last rMenB+OMV NZ vaccination in parent study and Day 1(prior to booster dose); Group B_0_1: Day 1(prior to first dose)</time_frame>
        <population>Analysis was performed on the Full analysis set (FAS) persistence. The FAS included all follow-on subjects (Group 3B) in the All Enrolled Set, and all naïve subjects (group B_0_1) in the All Enrolled Set who provided evaluable immunogenicity result at day 1, for at least one indicator strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B (V72_41)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1-month schedule in study V72_41 (NCT0142384) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72_41, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group 3B (V72P10)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72P10, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O3">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O4">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O5">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O6">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA Geometric Mean Titers (GMTs) After the Last Dose of rMenB+OMV NZ Vaccination in the Parent Study.</title>
          <description>Bactericidal activity was measured against each of the N. meningitidis group B indicator strains H44/76,5/99, NZ98/254 a nd M10713.</description>
          <population>Analysis was performed on the Full analysis set (FAS) persistence. The FAS included all follow-on subjects (Group 3B) in the All Enrolled Set, and all naïve subjects (group B_0_1) in the All Enrolled Set who provided evaluable immunogenicity result at day 1, for at least one indicator strain.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="275"/>
                <count group_id="O4" value="105"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76(1 month post last vacc in parent study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="275"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="82" upper_limit="119"/>
                    <measurement group_id="O2" value="197" lower_limit="165" upper_limit="235"/>
                    <measurement group_id="O3" value="124" lower_limit="108" upper_limit="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76( Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="275"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="150"/>
                    <count group_id="O6" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.43" lower_limit="2.04" upper_limit="2.89"/>
                    <measurement group_id="O2" value="4.51" lower_limit="3.57" upper_limit="5.69"/>
                    <measurement group_id="O3" value="3.05" lower_limit="2.61" upper_limit="3.56"/>
                    <measurement group_id="O4" value="1.14" lower_limit="0.93" upper_limit="1.40"/>
                    <measurement group_id="O5" value="1.52" lower_limit="1.23" upper_limit="1.90"/>
                    <measurement group_id="O6" value="1.20" lower_limit="1.02" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99(1 month post last vacc in parent study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="254"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180" lower_limit="153" upper_limit="211"/>
                    <measurement group_id="O2" value="606" lower_limit="492" upper_limit="746"/>
                    <measurement group_id="O3" value="270" lower_limit="234" upper_limit="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="254"/>
                    <count group_id="O4" value="100"/>
                    <count group_id="O5" value="139"/>
                    <count group_id="O6" value="239"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="19" upper_limit="30"/>
                    <measurement group_id="O2" value="31" lower_limit="23" upper_limit="42"/>
                    <measurement group_id="O3" value="26" lower_limit="21" upper_limit="31"/>
                    <measurement group_id="O4" value="1.20" lower_limit="0.91" upper_limit="1.58"/>
                    <measurement group_id="O5" value="2.30" lower_limit="1.75" upper_limit="3.04"/>
                    <measurement group_id="O6" value="1.57" lower_limit="1.26" upper_limit="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254(1 month post last vacc in parent study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="129"/>
                    <count group_id="O3" value="273"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="8.67" upper_limit="14"/>
                    <measurement group_id="O2" value="93" lower_limit="75" upper_limit="117"/>
                    <measurement group_id="O3" value="22" lower_limit="19" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254( Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="129"/>
                    <count group_id="O3" value="273"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="148"/>
                    <count group_id="O6" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" lower_limit="1.17" upper_limit="1.45"/>
                    <measurement group_id="O2" value="2.56" lower_limit="2.07" upper_limit="3.17"/>
                    <measurement group_id="O3" value="1.66" lower_limit="1.46" upper_limit="1.89"/>
                    <measurement group_id="O4" value="1.01" lower_limit="0.89" upper_limit="1.14"/>
                    <measurement group_id="O5" value="1.50" lower_limit="1.23" upper_limit="1.84"/>
                    <measurement group_id="O6" value="1.11" lower_limit="0.97" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713(1 month post last vacc in parent study)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="140"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="271"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="7.65" upper_limit="14"/>
                    <measurement group_id="O2" value="66" lower_limit="53" upper_limit="81"/>
                    <measurement group_id="O3" value="19" lower_limit="16" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713(Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="140"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="271"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="150"/>
                    <count group_id="O6" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="9.86" upper_limit="18"/>
                    <measurement group_id="O2" value="22" lower_limit="16" upper_limit="29"/>
                    <measurement group_id="O3" value="16" lower_limit="13" upper_limit="20"/>
                    <measurement group_id="O4" value="10" lower_limit="7.13" upper_limit="15"/>
                    <measurement group_id="O5" value="18" lower_limit="14" upper_limit="24"/>
                    <measurement group_id="O6" value="12" lower_limit="9.86" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for H44/76 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison at Persistence at 4 years/Baseline in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>vaccine group ratio of GMTs</param_type>
            <param_value>2.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.07</ci_lower_limit>
            <ci_upper_limit>3.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for H44/76 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison at Persistence at 4 years/Baseline in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>vaccine group ratio of GMTs</param_type>
            <param_value>2.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.66</ci_lower_limit>
            <ci_upper_limit>2.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for H44/76 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison at Persistence at 4 years/Baseline in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>vaccine group ratio of GMTs</param_type>
            <param_value>2.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.15</ci_lower_limit>
            <ci_upper_limit>4.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for 5/99 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison at Persistence at 4 years/Baseline in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>Vaccine group ratio of GMTs</param_type>
            <param_value>16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12</ci_lower_limit>
            <ci_upper_limit>21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for 5/99 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison at Persistence at 4 years/Baseline in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>vaccine group ratio of GMTs</param_type>
            <param_value>20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14</ci_lower_limit>
            <ci_upper_limit>28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for 5/99 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison at Persistence at 4 years/Baseline in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>vaccine group ratio of GMTs</param_type>
            <param_value>14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.05</ci_lower_limit>
            <ci_upper_limit>20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for NZ98/254 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison at Persistence at 4 years/Baseline in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>Vaccine group ratio of GMTs</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.26</ci_lower_limit>
            <ci_upper_limit>1.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for NZ98/254 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison at Persistence at 4 years/Baseline in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>vaccine group ratio of GMTs</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for NZ98/254 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison at Persistence at 4 years/Baseline in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>vaccine group ratio of GMTs</param_type>
            <param_value>1.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.27</ci_lower_limit>
            <ci_upper_limit>2.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for M10713 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison at Persistence at 4 years/Baseline in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>Vaccine group ratio of GMTs</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for M10713 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison at Persistence at 4 years/Baseline in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>vaccine group ratio of GMTs</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for M10713 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison at Persistence at 4 years/Baseline in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>vaccine group ratio of GMTs</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratios (GMRs) of GMTs After the Last Dose of rMenB+OMV NZ Vaccination in the Parent Study Versus Day 1.</title>
        <description>The GMRs of GMTs at Day 1 versus one month after the last dose of rMenB+OMV NZ vaccination in the parent study were calculated. Bactericidal activity was measured against each of the N. meningitidis group B indicator strains H44/76, 5/99,NZ98/254 and M10713.</description>
        <time_frame>Group 3B: 1 month after the last vaccination in parent study and Day 1 (prior to booster dose)</time_frame>
        <population>Analysis was performed on the Full analysis set (FAS) persistence. The FAS included all follow-on subjects (Group 3B) in the All Enrolled Set, and all naïve subjects (B_0_1) in the All Enrolled Set who provided evaluable immunogenicity result at day 1, for at least one indicator strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B (V72_41)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1-month schedule in study V72_41 (NCT0142384) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72_41, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group 3B (V72P10)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72P10, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O3">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratios (GMRs) of GMTs After the Last Dose of rMenB+OMV NZ Vaccination in the Parent Study Versus Day 1.</title>
          <description>The GMRs of GMTs at Day 1 versus one month after the last dose of rMenB+OMV NZ vaccination in the parent study were calculated. Bactericidal activity was measured against each of the N. meningitidis group B indicator strains H44/76, 5/99,NZ98/254 and M10713.</description>
          <population>Analysis was performed on the Full analysis set (FAS) persistence. The FAS included all follow-on subjects (Group 3B) in the All Enrolled Set, and all naïve subjects (B_0_1) in the All Enrolled Set who provided evaluable immunogenicity result at day 1, for at least one indicator strain.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="275"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.026" lower_limit="0.020" upper_limit="0.033"/>
                    <measurement group_id="O2" value="0.023" lower_limit="0.018" upper_limit="0.029"/>
                    <measurement group_id="O3" value="0.025" lower_limit="0.020" upper_limit="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="0.10" upper_limit="0.18"/>
                    <measurement group_id="O2" value="0.052" lower_limit="0.039" upper_limit="0.068"/>
                    <measurement group_id="O3" value="0.098" lower_limit="0.079" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="129"/>
                    <count group_id="O3" value="273"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="0.092" upper_limit="0.15"/>
                    <measurement group_id="O2" value="0.027" lower_limit="0.021" upper_limit="0.036"/>
                    <measurement group_id="O3" value="0.073" lower_limit="0.059" upper_limit="0.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="140"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="271"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" lower_limit="0.92" upper_limit="1.73"/>
                    <measurement group_id="O2" value="0.33" lower_limit="0.25" upper_limit="0.43"/>
                    <measurement group_id="O3" value="0.81" lower_limit="0.65" upper_limit="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Solicited Local and Systemic AEs.</title>
        <description>Solicited adverse events are signs and symptoms derived from organized data collection systems, such as Subject Diaries or interview. The percentage and frequencies of subjects reporting solicited local and systemic AEs were tabulated. Threshold for any Erythema, Swelling and Induration: &gt;= 25 mm Note:Vaccination 2 was performed only on group B_0_1 subjects. Threshold for any Erythema, Swelling and Induration: &gt;= 25 mm</description>
        <time_frame>7 days (including the day of vaccination) after each vaccination</time_frame>
        <population>The analysis was done on the Solicited Safety Set. The solicited safety set included all subjects in the exposed set with any solicited adverse event data and/indicators of solicited adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local and Systemic AEs.</title>
          <description>Solicited adverse events are signs and symptoms derived from organized data collection systems, such as Subject Diaries or interview. The percentage and frequencies of subjects reporting solicited local and systemic AEs were tabulated. Threshold for any Erythema, Swelling and Induration: &gt;= 25 mm Note:Vaccination 2 was performed only on group B_0_1 subjects. Threshold for any Erythema, Swelling and Induration: &gt;= 25 mm</description>
          <population>The analysis was done on the Solicited Safety Set. The solicited safety set included all subjects in the exposed set with any solicited adverse event data and/indicators of solicited adverse events.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263"/>
                    <measurement group_id="O2" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Local (vaccination 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258"/>
                    <measurement group_id="O2" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain (vaccination 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="264"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258"/>
                    <measurement group_id="O2" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (vaccination 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="261"/>
                    <count group_id="O2" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (vaccination 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="261"/>
                    <count group_id="O2" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (vaccination 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="261"/>
                    <count group_id="O2" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic (vaccination 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                    <measurement group_id="O2" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥ 38.0°C) (vaccination 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="265"/>
                    <count group_id="O2" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High fever (≥ 39.5°C) (vaccination 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="265"/>
                    <count group_id="O2" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (vaccination 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="264"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (vaccination 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (vaccination 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="265"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (vaccination 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="265"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (vaccination 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Local (vaccination 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain (vaccination 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (vaccination 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (vaccination 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (vaccination 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic (vaccination 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥ 38.0°C) (vaccination 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High fever (≥ 39.5°C) (vaccination 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (vaccination 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (vaccination 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (vaccination 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (vaccination 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (vaccination 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any Unsolicited Adverse Events (AEs).</title>
        <description>An unsolicited adverse event is an adverse event that was not solicited using a subject Diary and that was spontaneously communicated by a subject and/or parent(s)/legal guardian(s) who has signed the informed consent. Note : Vaccination 2 was performed only on group B_0_1 subjects.</description>
        <time_frame>30 days (including the day of vaccination) after each vaccination.</time_frame>
        <population>Analysis was performed on the unsolicited safety set. The unsolicited safety set included all subjects who received a study vaccination with unsolicited adverse event data.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Unsolicited Adverse Events (AEs).</title>
          <description>An unsolicited adverse event is an adverse event that was not solicited using a subject Diary and that was spontaneously communicated by a subject and/or parent(s)/legal guardian(s) who has signed the informed consent. Note : Vaccination 2 was performed only on group B_0_1 subjects.</description>
          <population>Analysis was performed on the unsolicited safety set. The unsolicited safety set included all subjects who received a study vaccination with unsolicited adverse event data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any unsolicited AEs ( vaccination 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any unsolicited AEs (vaccination 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any SAEs, AEs Leading to Withdrawal and Medically Attended AEs.</title>
        <description>A serious adverse event is any untoward medical occurrence that at any dose results in death or is life threatening or requires prolonged hospitalization, leads to Persistent or significant disability/incapacity.</description>
        <time_frame>Group 3B: from Day 1 to Day 31 (study termination visit) and Group B_0_1: from Day 1 to Day 61 (study termination visit)</time_frame>
        <population>Analysis was performed on the Overall safety set. The overall safety set included all screened subjects in the solicited and unsolicited safety set who provided informed consent and provided demographic and/or baseline screening assessments, regardless of the subject’s randomization and treatment status in the study and received a Subject ID.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any SAEs, AEs Leading to Withdrawal and Medically Attended AEs.</title>
          <description>A serious adverse event is any untoward medical occurrence that at any dose results in death or is life threatening or requires prolonged hospitalization, leads to Persistent or significant disability/incapacity.</description>
          <population>Analysis was performed on the Overall safety set. The overall safety set included all screened subjects in the solicited and unsolicited safety set who provided informed consent and provided demographic and/or baseline screening assessments, regardless of the subject’s randomization and treatment status in the study and received a Subject ID.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Medically Attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AEs leading to premature withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA ≥1:5 After Booster Dose/First Vaccination of rMenB+OMV NZ.</title>
        <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.</description>
        <time_frame>Group 3B: 30 days after booster dose, Group B_0_1 : 30 days after first vaccination.</time_frame>
        <population>Analysis was performed on the Full Analysis set( FAS) booster. The FAS booster included all follow on subjects and all naive subjects in the All enrolled set who received vaccination at day 1 and provided evaluable immunogenicity result at day 31 for at least one indicator strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B (V72_41)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1-month schedule in study V72_41 (NCT0142384) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72_41, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group 3B (V72P10)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72P10, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O3">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O4">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O5">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O6">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥1:5 After Booster Dose/First Vaccination of rMenB+OMV NZ.</title>
          <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.</description>
          <population>Analysis was performed on the Full Analysis set( FAS) booster. The FAS booster included all follow on subjects and all naive subjects in the All enrolled set who received vaccination at day 1 and provided evaluable immunogenicity result at day 31 for at least one indicator strain.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="268"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="149"/>
                <count group_id="O6" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="268"/>
                    <count group_id="O4" value="104"/>
                    <count group_id="O5" value="149"/>
                    <count group_id="O6" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="93.9" upper_limit="99.56"/>
                    <measurement group_id="O2" value="100" lower_limit="97.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99" lower_limit="96.8" upper_limit="99.77"/>
                    <measurement group_id="O4" value="80" lower_limit="70.8" upper_limit="87.0"/>
                    <measurement group_id="O5" value="79" lower_limit="71.1" upper_limit="84.8"/>
                    <measurement group_id="O6" value="79" lower_limit="73.5" upper_limit="83.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="226"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="137"/>
                    <count group_id="O6" value="234"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.4" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="86" lower_limit="77.0" upper_limit="91.9"/>
                    <measurement group_id="O5" value="83" lower_limit="75.9" upper_limit="89.0"/>
                    <measurement group_id="O6" value="84" lower_limit="78.9" upper_limit="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="262"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="148"/>
                    <count group_id="O6" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="86.6" upper_limit="96.1"/>
                    <measurement group_id="O2" value="93" lower_limit="87.3" upper_limit="97.1"/>
                    <measurement group_id="O3" value="93" lower_limit="88.9" upper_limit="95.6"/>
                    <measurement group_id="O4" value="40" lower_limit="30.3" upper_limit="49.9"/>
                    <measurement group_id="O5" value="60" lower_limit="51.8" upper_limit="68.1"/>
                    <measurement group_id="O6" value="52" lower_limit="45.4" upper_limit="58.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="268"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="149"/>
                    <count group_id="O6" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96.1" upper_limit="99.98"/>
                    <measurement group_id="O2" value="98" lower_limit="94.4" upper_limit="99.81"/>
                    <measurement group_id="O3" value="99" lower_limit="96.8" upper_limit="99.77"/>
                    <measurement group_id="O4" value="80" lower_limit="70.5" upper_limit="86.9"/>
                    <measurement group_id="O5" value="92" lower_limit="86.4" upper_limit="95.8"/>
                    <measurement group_id="O6" value="87" lower_limit="82.1" upper_limit="90.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.0</ci_lower_limit>
            <ci_upper_limit>25.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.7</ci_lower_limit>
            <ci_upper_limit>27.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.6</ci_lower_limit>
            <ci_upper_limit>28.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.7</ci_lower_limit>
            <ci_upper_limit>21.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.8</ci_lower_limit>
            <ci_upper_limit>22.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.4</ci_lower_limit>
            <ci_upper_limit>23.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>33.9</ci_lower_limit>
            <ci_upper_limit>47.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>41.6</ci_lower_limit>
            <ci_upper_limit>62.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.9</ci_lower_limit>
            <ci_upper_limit>42.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.0</ci_lower_limit>
            <ci_upper_limit>16.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.8</ci_lower_limit>
            <ci_upper_limit>28.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.5</ci_lower_limit>
            <ci_upper_limit>12.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA ≥1:8 After Booster Dose/First Vaccination of rMenB+OMV NZ</title>
        <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.</description>
        <time_frame>Group 3B : 30 days after booster dose, Group B_0_1 : 30 days after first vaccination.</time_frame>
        <population>Analysis was performed on the Full Analysis set( FAS) booster. The FAS booster included all follow on subjects and all naive subjects in the All enrolled set who received vaccination at day 1 and provided evaluable immunogenicity result at day 31 for at least one indicator strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B (V72_41)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1-month schedule in study V72_41 (NCT0142384) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72_41, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group 3B (V72P10)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72P10, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O3">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O4">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O5">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O6">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥1:8 After Booster Dose/First Vaccination of rMenB+OMV NZ</title>
          <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.</description>
          <population>Analysis was performed on the Full Analysis set( FAS) booster. The FAS booster included all follow on subjects and all naive subjects in the All enrolled set who received vaccination at day 1 and provided evaluable immunogenicity result at day 31 for at least one indicator strain.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="268"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="149"/>
                <count group_id="O6" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="268"/>
                    <count group_id="O4" value="104"/>
                    <count group_id="O5" value="149"/>
                    <count group_id="O6" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="93.9" upper_limit="99.56"/>
                    <measurement group_id="O2" value="100" lower_limit="97.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99" lower_limit="96.8" upper_limit="99.77"/>
                    <measurement group_id="O4" value="67" lower_limit="57.4" upper_limit="76.2"/>
                    <measurement group_id="O5" value="74" lower_limit="66.7" upper_limit="81.3"/>
                    <measurement group_id="O6" value="72" lower_limit="65.6" upper_limit="77.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="226"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="137"/>
                    <count group_id="O6" value="234"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.1" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96.4" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="81" lower_limit="72.3" upper_limit="88.6"/>
                    <measurement group_id="O5" value="81" lower_limit="73.4" upper_limit="87.2"/>
                    <measurement group_id="O6" value="81" lower_limit="75.6" upper_limit="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="262"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="148"/>
                    <count group_id="O6" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="79.1" upper_limit="91.2"/>
                    <measurement group_id="O2" value="89" lower_limit="82.2" upper_limit="94.1"/>
                    <measurement group_id="O3" value="87" lower_limit="82.8" upper_limit="91.2"/>
                    <measurement group_id="O4" value="28" lower_limit="19.7" upper_limit="37.9"/>
                    <measurement group_id="O5" value="56" lower_limit="47.7" upper_limit="64.2"/>
                    <measurement group_id="O6" value="45" lower_limit="38.4" upper_limit="51.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="268"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="149"/>
                    <count group_id="O6" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95.0" upper_limit="99.83"/>
                    <measurement group_id="O2" value="98" lower_limit="93.3" upper_limit="99.51"/>
                    <measurement group_id="O3" value="98" lower_limit="95.7" upper_limit="99.4"/>
                    <measurement group_id="O4" value="79" lower_limit="69.5" upper_limit="86.1"/>
                    <measurement group_id="O5" value="89" lower_limit="83.1" upper_limit="93.7"/>
                    <measurement group_id="O6" value="85" lower_limit="79.9" upper_limit="89.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.9</ci_lower_limit>
            <ci_upper_limit>33.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.8</ci_lower_limit>
            <ci_upper_limit>40.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.2</ci_lower_limit>
            <ci_upper_limit>33.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.3</ci_lower_limit>
            <ci_upper_limit>24.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.1</ci_lower_limit>
            <ci_upper_limit>27.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.3</ci_lower_limit>
            <ci_upper_limit>26.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>35.2</ci_lower_limit>
            <ci_upper_limit>49.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>46.6</ci_lower_limit>
            <ci_upper_limit>67.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.0</ci_lower_limit>
            <ci_upper_limit>42.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.8</ci_lower_limit>
            <ci_upper_limit>18.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.6</ci_lower_limit>
            <ci_upper_limit>29.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference were calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.7</ci_lower_limit>
            <ci_upper_limit>14.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA ≥1:16 After Booster Dose/First Vaccination of rMenB+OMV NZ</title>
        <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76, 5/99, NZ98/254 &amp; M10713.</description>
        <time_frame>Group 3B: 30 days after booster dose, Group B_0_1 : 30 days after first vaccination.</time_frame>
        <population>Analysis was performed on the Full Analysis set( FAS) booster. The FAS booster included all follow on subjects and all naive subjects in the All enrolled set who received vaccination at day 1 and provided evaluable immunogenicity result at day 31 for at least one indicator strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B (V72_41)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1-month schedule in study V72_41 (NCT0142384) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72_41, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group 3B (V72P10)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72P10, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O3">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O4">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O5">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O6">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥1:16 After Booster Dose/First Vaccination of rMenB+OMV NZ</title>
          <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76, 5/99, NZ98/254 &amp; M10713.</description>
          <population>Analysis was performed on the Full Analysis set( FAS) booster. The FAS booster included all follow on subjects and all naive subjects in the All enrolled set who received vaccination at day 1 and provided evaluable immunogenicity result at day 31 for at least one indicator strain.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="268"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="149"/>
                <count group_id="O6" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="268"/>
                    <count group_id="O4" value="104"/>
                    <count group_id="O5" value="149"/>
                    <count group_id="O6" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="93.9" upper_limit="99.56"/>
                    <measurement group_id="O2" value="99" lower_limit="95.7" upper_limit="99.98"/>
                    <measurement group_id="O3" value="99" lower_limit="96.2" upper_limit="99.59"/>
                    <measurement group_id="O4" value="49" lower_limit="39.1" upper_limit="59.0"/>
                    <measurement group_id="O5" value="65" lower_limit="56.9" upper_limit="72.7"/>
                    <measurement group_id="O6" value="58" lower_limit="52.2" upper_limit="64.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="226"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="137"/>
                    <count group_id="O6" value="234"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.1" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96.4" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="77" lower_limit="67.7" upper_limit="85.2"/>
                    <measurement group_id="O5" value="70" lower_limit="61.7" upper_limit="77.6"/>
                    <measurement group_id="O6" value="73" lower_limit="66.9" upper_limit="78.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="262"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="148"/>
                    <count group_id="O6" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="65.2" upper_limit="80.3"/>
                    <measurement group_id="O2" value="86" lower_limit="78.3" upper_limit="91.5"/>
                    <measurement group_id="O3" value="79" lower_limit="73.6" upper_limit="83.8"/>
                    <measurement group_id="O4" value="22" lower_limit="14.7" upper_limit="31.6"/>
                    <measurement group_id="O5" value="45" lower_limit="37.1" upper_limit="53.7"/>
                    <measurement group_id="O6" value="36" lower_limit="29.9" upper_limit="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="268"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="149"/>
                    <count group_id="O6" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="88.2" upper_limit="97.0"/>
                    <measurement group_id="O2" value="97" lower_limit="92.1" upper_limit="99.1"/>
                    <measurement group_id="O3" value="95" lower_limit="91.8" upper_limit="97.4"/>
                    <measurement group_id="O4" value="66" lower_limit="56.0" upper_limit="75.1"/>
                    <measurement group_id="O5" value="84" lower_limit="77.0" upper_limit="89.4"/>
                    <measurement group_id="O6" value="77" lower_limit="70.9" upper_limit="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>33.9</ci_lower_limit>
            <ci_upper_limit>46.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>38.9</ci_lower_limit>
            <ci_upper_limit>58.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>26.6</ci_lower_limit>
            <ci_upper_limit>42.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.6</ci_lower_limit>
            <ci_upper_limit>33.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.5</ci_lower_limit>
            <ci_upper_limit>32.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.9</ci_lower_limit>
            <ci_upper_limit>38.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>35.1</ci_lower_limit>
            <ci_upper_limit>50.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>39.3</ci_lower_limit>
            <ci_upper_limit>60.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29.9</ci_lower_limit>
            <ci_upper_limit>50.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 (Group 3B vs. Group B_0_1)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.9</ci_lower_limit>
            <ci_upper_limit>24.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.9</ci_lower_limit>
            <ci_upper_limit>37.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at 1 month after booster /1st dose in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.4</ci_lower_limit>
            <ci_upper_limit>20.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA Geometric Mean Titers Prior to Booster/First Dose of Vaccination &amp; Post Booster/First Dose of Vaccination.</title>
        <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76, 5/99,NZ98/254 and M10713.</description>
        <time_frame>Group 3B subjects: Day 1(pre-booster dose) and 30 days post-booster dose. Group B_0_1: Day 1 (pre-first dose) and 30 days post-first dose.</time_frame>
        <population>Analysis was performed on the Full Analysis set( FAS) booster. The FAS booster included all follow on subjects and all naive subjects in the All enrolled set who received vaccination at day 1 and provided evaluable immunogenicity result at day 31 for at least one indicator strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B (V72_41)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1-month schedule in study V72_41 (NCT0142384) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72_41, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group 3B (V72P10)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72P10, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O3">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O4">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O5">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O6">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA Geometric Mean Titers Prior to Booster/First Dose of Vaccination &amp; Post Booster/First Dose of Vaccination.</title>
          <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76, 5/99,NZ98/254 and M10713.</description>
          <population>Analysis was performed on the Full Analysis set( FAS) booster. The FAS booster included all follow on subjects and all naive subjects in the All enrolled set who received vaccination at day 1 and provided evaluable immunogenicity result at day 31 for at least one indicator strain.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="268"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="149"/>
                <count group_id="O6" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76- pre booster/ pre first dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="268"/>
                    <count group_id="O4" value="104"/>
                    <count group_id="O5" value="149"/>
                    <count group_id="O6" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" lower_limit="2.06" upper_limit="2.92"/>
                    <measurement group_id="O2" value="4.65" lower_limit="3.66" upper_limit="5.89"/>
                    <measurement group_id="O3" value="3.10" lower_limit="2.65" upper_limit="3.62"/>
                    <measurement group_id="O4" value="1.13" lower_limit="0.92" upper_limit="1.38"/>
                    <measurement group_id="O5" value="1.53" lower_limit="1.23" upper_limit="1.90"/>
                    <measurement group_id="O6" value="1.19" lower_limit="1.01" upper_limit="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76-1 month post booster/first dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="268"/>
                    <count group_id="O4" value="104"/>
                    <count group_id="O5" value="149"/>
                    <count group_id="O6" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158" lower_limit="123" upper_limit="204"/>
                    <measurement group_id="O2" value="269" lower_limit="206" upper_limit="351"/>
                    <measurement group_id="O3" value="188" lower_limit="155" upper_limit="228"/>
                    <measurement group_id="O4" value="13" lower_limit="10" upper_limit="18"/>
                    <measurement group_id="O5" value="24" lower_limit="19" upper_limit="31"/>
                    <measurement group_id="O6" value="16" lower_limit="13" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99- pre booster/ pre first dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="211"/>
                    <count group_id="O4" value="96"/>
                    <count group_id="O5" value="129"/>
                    <count group_id="O6" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="17" upper_limit="28"/>
                    <measurement group_id="O2" value="31" lower_limit="22" upper_limit="43"/>
                    <measurement group_id="O3" value="24" lower_limit="19" upper_limit="30"/>
                    <measurement group_id="O4" value="1.19" lower_limit="0.89" upper_limit="1.59"/>
                    <measurement group_id="O5" value="2.19" lower_limit="1.65" upper_limit="2.92"/>
                    <measurement group_id="O6" value="1.51" lower_limit="1.21" upper_limit="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99-1 month post booster/first dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="226"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="137"/>
                    <count group_id="O6" value="234"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2191" lower_limit="1681" upper_limit="2856"/>
                    <measurement group_id="O2" value="1951" lower_limit="1425" upper_limit="2671"/>
                    <measurement group_id="O3" value="2089" lower_limit="1690" upper_limit="2582"/>
                    <measurement group_id="O4" value="30" lower_limit="22" upper_limit="40"/>
                    <measurement group_id="O5" value="31" lower_limit="24" upper_limit="41"/>
                    <measurement group_id="O6" value="31" lower_limit="25" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254-pre booster/ pre first dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="118"/>
                    <count group_id="O3" value="260"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="146"/>
                    <count group_id="O6" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" lower_limit="1.18" upper_limit="1.46"/>
                    <measurement group_id="O2" value="2.48" lower_limit="1.99" upper_limit="3.09"/>
                    <measurement group_id="O3" value="1.64" lower_limit="1.44" upper_limit="1.86"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.88" upper_limit="1.13"/>
                    <measurement group_id="O5" value="1.51" lower_limit="1.24" upper_limit="1.84"/>
                    <measurement group_id="O6" value="1.11" lower_limit="0.97" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254-1 month post booster/first dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="262"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="148"/>
                    <count group_id="O6" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="23" upper_limit="38"/>
                    <measurement group_id="O2" value="41" lower_limit="30" upper_limit="56"/>
                    <measurement group_id="O3" value="32" lower_limit="26" upper_limit="39"/>
                    <measurement group_id="O4" value="3.58" lower_limit="2.70" upper_limit="4.76"/>
                    <measurement group_id="O5" value="9.43" lower_limit="7.15" upper_limit="12"/>
                    <measurement group_id="O6" value="5.39" lower_limit="4.33" upper_limit="6.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713-pre booster/ pre first dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="140"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="267"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="149"/>
                    <count group_id="O6" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="10" upper_limit="19"/>
                    <measurement group_id="O2" value="22" lower_limit="16" upper_limit="29"/>
                    <measurement group_id="O3" value="16" lower_limit="13" upper_limit="20"/>
                    <measurement group_id="O4" value="9.82" lower_limit="6.87" upper_limit="14"/>
                    <measurement group_id="O5" value="18" lower_limit="14" upper_limit="23"/>
                    <measurement group_id="O6" value="12" lower_limit="9.62" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713-1 month post booster/first dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="268"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="149"/>
                    <count group_id="O6" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="52" upper_limit="81"/>
                    <measurement group_id="O2" value="113" lower_limit="90" upper_limit="142"/>
                    <measurement group_id="O3" value="78" lower_limit="66" upper_limit="92"/>
                    <measurement group_id="O4" value="23" lower_limit="18" upper_limit="30"/>
                    <measurement group_id="O5" value="46" lower_limit="37" upper_limit="57"/>
                    <measurement group_id="O6" value="30" lower_limit="25" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Pre booster/Pre first dose-Adjusted geometric mean titers for H44/76 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison Pre-booster or pre-1st dose in V72_75 (Group 3B vs. Group B
_0_1)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>2.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.11</ci_lower_limit>
            <ci_upper_limit>3.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Post booster/Post first dose-Adjusted geometric mean titers for H44/76 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison Post-booster or post-1st dose in V72_75 (Group 3B vs. Group B
_0_1)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.85</ci_lower_limit>
            <ci_upper_limit>15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Pre booster/Pre first dose-Adjusted geometric mean titers for H44/76 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison-Pre-booster or pre-1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>2.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.70</ci_lower_limit>
            <ci_upper_limit>2.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post booster/Post first dose-Adjusted geometric mean titers for H44/76 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison-post-booster or post-1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.22</ci_lower_limit>
            <ci_upper_limit>17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Pre booster/Pre first dose-Adjusted geometric mean titers for H44/76 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison- Pre-booster or pre-1st dose in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>3.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.20</ci_lower_limit>
            <ci_upper_limit>4.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Post booster/Post first dose-Adjusted geometric mean titers for H44/76 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison- post-booster or post-1st dose in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.75</ci_lower_limit>
            <ci_upper_limit>16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Pre booster/Pre first dose-Adjusted geometric mean titers for 5/99 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison Pre-booster or pre-1st dose in V72_75 (Group 3B vs. Group B
_0_1)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12</ci_lower_limit>
            <ci_upper_limit>21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Post booster/Post first dose-Adjusted geometric mean titers for 5/99 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison Post-booster or post-1st dose in V72_75 (Group 3B vs. Group B
_0_1)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>51</ci_lower_limit>
            <ci_upper_limit>90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Pre booster/Pre first dose-Adjusted geometric mean titers for 5/99 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison- Pre-booster or pre-1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13</ci_lower_limit>
            <ci_upper_limit>26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post booster/Post first dose-Adjusted geometric mean titers for 5/99 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison- post-booster or post-1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>51</ci_lower_limit>
            <ci_upper_limit>107</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Pre booster/Pre first dose-Adjusted geometric mean titers for 5/99 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison- Pre-booster or pre-1st dose in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.99</ci_lower_limit>
            <ci_upper_limit>22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Post booster/Post first dose-Adjusted geometric mean titers for 5/99 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison- post-booster or post-1st dose in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>41</ci_lower_limit>
            <ci_upper_limit>95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Pre booster/Pre first dose-Adjusted geometric mean titers for NZ98/254 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison Pre-booster or pre-1st dose in V72_75 (Group 3B vs. Group B
_0_1)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.24</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Post booster dose/ post first dose-Adjusted geometric mean titers for NZ98/254 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison Post-booster or post-1st dose in V72_75 (Group 3B vs. Group B
_0_1)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>5.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.49</ci_lower_limit>
            <ci_upper_limit>7.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Pre booster/Pre first dose-Adjusted geometric mean titers for NZ98/254 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison- Pre-booster or pre-1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post booster/Post first dose-Adjusted geometric mean titers for NZ98/254 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison- post-booster or post-1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>8.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.83</ci_lower_limit>
            <ci_upper_limit>12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Pre booster/Pre first dose-Adjusted geometric mean titers for NZ98/254 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison- Pre-booster or pre-1st dose in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.22</ci_lower_limit>
            <ci_upper_limit>2.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Post booster/Post first dose-Adjusted geometric mean titers for NZ98/254 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison- post-booster or post-1st dose in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>4.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.88</ci_lower_limit>
            <ci_upper_limit>6.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Pre booster/Pre first dose-Adjusted geometric mean titers for M10713 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison Pre-booster or pre-1st dose in V72_75 (Group 3B vs. Group B
_0_1)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Post booster/Post first dose-Adjusted geometric mean titers for M10713 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison Post-booster or post-1st dose in V72_75 (Group 3B vs. Group B
_0_1)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>2.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.08</ci_lower_limit>
            <ci_upper_limit>3.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Pre booster/Pre first dose-Adjusted geometric mean titers for M10713 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison- Pre-booster or pre-1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>2.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post booster/Post first dose-Adjusted geometric mean titers for M10713 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison- post-booster or post-1st dose in V72_75 [Group 3B (V72_41) vs. Group B_0_1 (V72_41)]</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>2.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.04</ci_lower_limit>
            <ci_upper_limit>3.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Pre booster/Pre first dose-Adjusted geometric mean titers for M10713 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison- Pre-booster or pre-1st dose in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Post booster/Post first dose-Adjusted geometric mean titers for M10713 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison- post-booster or post-1st dose in V72_75 [Group 3B (V72P10) vs. Group B_0_1 (V72P10)]</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>2.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.79</ci_lower_limit>
            <ci_upper_limit>3.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratio (GMRs) of GMTs After Booster Dose/First rMenB+OMV NZ Vaccination Versus Day 1.</title>
        <description>Bactericidal activity was measured against each of the fout N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713 by calculating the GMRs of GMTs one month post-vaccination of a booster dose versus pre-booster dose (follow-on subjects) or first dose of rMenB+OMV NZ versus prefirst dose (naïve subjects) to each N. meningitidis group B indicator strain.</description>
        <time_frame>At Day 31 (30 days post booster dose/first dose of vaccination) versus Day 1 (prior to booster dose/first dose of vaccination).</time_frame>
        <population>Analysis was performed on the Full Analysis set( FAS) booster. The FAS booster included all follow on subjects and all naive subjects in the All enrolled set who received vaccination at day 1 and provided evaluable immunogenicity result at day 31 for at least one indicator strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B (V72_41)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1-month schedule in study V72_41 (NCT0142384) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72_41, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group 3B (V72P10)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72P10, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O3">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O4">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O5">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O6">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio (GMRs) of GMTs After Booster Dose/First rMenB+OMV NZ Vaccination Versus Day 1.</title>
          <description>Bactericidal activity was measured against each of the fout N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713 by calculating the GMRs of GMTs one month post-vaccination of a booster dose versus pre-booster dose (follow-on subjects) or first dose of rMenB+OMV NZ versus prefirst dose (naïve subjects) to each N. meningitidis group B indicator strain.</description>
          <population>Analysis was performed on the Full Analysis set( FAS) booster. The FAS booster included all follow on subjects and all naive subjects in the All enrolled set who received vaccination at day 1 and provided evaluable immunogenicity result at day 31 for at least one indicator strain.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="268"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="149"/>
                <count group_id="O6" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="268"/>
                    <count group_id="O4" value="104"/>
                    <count group_id="O5" value="149"/>
                    <count group_id="O6" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="49" upper_limit="85"/>
                    <measurement group_id="O2" value="58" lower_limit="44" upper_limit="76"/>
                    <measurement group_id="O3" value="61" lower_limit="50" upper_limit="74"/>
                    <measurement group_id="O4" value="12" lower_limit="8.69" upper_limit="16"/>
                    <measurement group_id="O5" value="16" lower_limit="12" upper_limit="20"/>
                    <measurement group_id="O6" value="14" lower_limit="11" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="211"/>
                    <count group_id="O4" value="96"/>
                    <count group_id="O5" value="129"/>
                    <count group_id="O6" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="72" upper_limit="139"/>
                    <measurement group_id="O2" value="64" lower_limit="44" upper_limit="93"/>
                    <measurement group_id="O3" value="87" lower_limit="67" upper_limit="112"/>
                    <measurement group_id="O4" value="25" lower_limit="18" upper_limit="36"/>
                    <measurement group_id="O5" value="14" lower_limit="9.90" upper_limit="19"/>
                    <measurement group_id="O6" value="20" lower_limit="16" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="118"/>
                    <count group_id="O3" value="260"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="146"/>
                    <count group_id="O6" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="18" upper_limit="29"/>
                    <measurement group_id="O2" value="16" lower_limit="12" upper_limit="22"/>
                    <measurement group_id="O3" value="19" lower_limit="16" upper_limit="24"/>
                    <measurement group_id="O4" value="3.60" lower_limit="2.69" upper_limit="4.81"/>
                    <measurement group_id="O5" value="6.43" lower_limit="4.95" upper_limit="8.34"/>
                    <measurement group_id="O6" value="4.92" lower_limit="3.97" upper_limit="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="140"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="267"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="149"/>
                    <count group_id="O6" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.69" lower_limit="3.72" upper_limit="5.92"/>
                    <measurement group_id="O2" value="5.16" lower_limit="4.14" upper_limit="6.42"/>
                    <measurement group_id="O3" value="4.85" lower_limit="4.10" upper_limit="5.72"/>
                    <measurement group_id="O4" value="2.37" lower_limit="1.81" upper_limit="3.10"/>
                    <measurement group_id="O5" value="2.58" lower_limit="2.11" upper_limit="3.16"/>
                    <measurement group_id="O6" value="2.44" lower_limit="2.04" upper_limit="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With at Least 4-fold Increase in hSBA Titers Pre Vaccination Compared to One Month Post-booster/First rMenB+OMV NZ Vaccination</title>
        <description>The percentage of subjects with 4-fold rise at one month post-vaccination with a booster dose (follow-on subjects) /first dose (naive subjects) of rMenB+OMV NZ with respect to day 1 (follow-on subjects) / pre-first dose of rMenB+OMV NZ (naïve subjects). Percentage of subjects with four-fold rise in hSBA titers relative to baseline were defined as: • for a pre-vaccination titer &lt; 4, a post-vaccination titer of at least 16; • for a pre-vaccination titer ≥ 4 but &lt;LLOQ, a post vaccination titer of at least fourfold the LLOQ; • for a pre-vaccination titer ≥LLOQ, a post vaccination titer of at least fourfold the pre-vaccination titer</description>
        <time_frame>Group 3B: 1 month after booster dose; Group B_0_1: 1 month after first vaccination</time_frame>
        <population>Analysis was performed on the Full Analysis set (FAS) booster. The FAS booster included all follow on subjects and all naive subjects in the All enrolled set who received vaccination at day 1 and provided evaluable immunogenicity result at day 31 for atleast one indicator strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B (V72_41)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1-month schedule in study V72_41 (NCT0142384) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72_41, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group 3B (V72P10)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72P10, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O3">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O4">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O5">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O6">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With at Least 4-fold Increase in hSBA Titers Pre Vaccination Compared to One Month Post-booster/First rMenB+OMV NZ Vaccination</title>
          <description>The percentage of subjects with 4-fold rise at one month post-vaccination with a booster dose (follow-on subjects) /first dose (naive subjects) of rMenB+OMV NZ with respect to day 1 (follow-on subjects) / pre-first dose of rMenB+OMV NZ (naïve subjects). Percentage of subjects with four-fold rise in hSBA titers relative to baseline were defined as: • for a pre-vaccination titer &lt; 4, a post-vaccination titer of at least 16; • for a pre-vaccination titer ≥ 4 but &lt;LLOQ, a post vaccination titer of at least fourfold the LLOQ; • for a pre-vaccination titer ≥LLOQ, a post vaccination titer of at least fourfold the pre-vaccination titer</description>
          <population>Analysis was performed on the Full Analysis set (FAS) booster. The FAS booster included all follow on subjects and all naive subjects in the All enrolled set who received vaccination at day 1 and provided evaluable immunogenicity result at day 31 for atleast one indicator strain.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="268"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="149"/>
                <count group_id="O6" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="268"/>
                    <count group_id="O4" value="104"/>
                    <count group_id="O5" value="149"/>
                    <count group_id="O6" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="90.0" upper_limit="98.0"/>
                    <measurement group_id="O2" value="98" lower_limit="93.3" upper_limit="99.51"/>
                    <measurement group_id="O3" value="96" lower_limit="93.2" upper_limit="98.2"/>
                    <measurement group_id="O4" value="66" lower_limit="56.4" upper_limit="75.3"/>
                    <measurement group_id="O5" value="72" lower_limit="63.9" upper_limit="78.9"/>
                    <measurement group_id="O6" value="70" lower_limit="63.5" upper_limit="75.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="211"/>
                    <count group_id="O4" value="96"/>
                    <count group_id="O5" value="129"/>
                    <count group_id="O6" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94.0" upper_limit="99.79"/>
                    <measurement group_id="O2" value="97" lower_limit="90.9" upper_limit="99.3"/>
                    <measurement group_id="O3" value="98" lower_limit="94.6" upper_limit="99.2"/>
                    <measurement group_id="O4" value="79" lower_limit="69.7" upper_limit="86.8"/>
                    <measurement group_id="O5" value="74" lower_limit="65.2" upper_limit="81.0"/>
                    <measurement group_id="O6" value="76" lower_limit="69.9" upper_limit="81.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="118"/>
                    <count group_id="O3" value="260"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="146"/>
                    <count group_id="O6" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="75.9" upper_limit="88.9"/>
                    <measurement group_id="O2" value="77" lower_limit="68.5" upper_limit="84.3"/>
                    <measurement group_id="O3" value="80" lower_limit="75.0" upper_limit="85.0"/>
                    <measurement group_id="O4" value="28" lower_limit="19.7" upper_limit="37.9"/>
                    <measurement group_id="O5" value="53" lower_limit="44.3" upper_limit="61.1"/>
                    <measurement group_id="O6" value="43" lower_limit="36.3" upper_limit="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="140"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="267"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="149"/>
                    <count group_id="O6" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="40.0" upper_limit="57.2"/>
                    <measurement group_id="O2" value="49" lower_limit="39.9" upper_limit="57.8"/>
                    <measurement group_id="O3" value="49" lower_limit="42.6" upper_limit="54.9"/>
                    <measurement group_id="O4" value="24" lower_limit="16.4" upper_limit="33.7"/>
                    <measurement group_id="O5" value="27" lower_limit="19.9" upper_limit="34.7"/>
                    <measurement group_id="O6" value="26" lower_limit="20.5" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month post booster/first dose of vaccination: Four-fold Increase (Group 3B vs. Group B_0_1) Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.7</ci_lower_limit>
            <ci_upper_limit>33.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month post booster/first dose of vaccination: Four-fold Increase [Group 3B (V72_41) vs. Group B_0_1 (V72_41) Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.3</ci_lower_limit>
            <ci_upper_limit>38.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month post booster/first dose of vaccination: Four-fold Increase [Group 3B (V72P10) vs. Group B_0_1 (V72P10) Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.3</ci_lower_limit>
            <ci_upper_limit>33.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval or the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month post booster/first dose of vaccination: Four-fold Increase (Group 3B vs. Group B_0_1) Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.9</ci_lower_limit>
            <ci_upper_limit>27.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month post booster/first dose of vaccination: Four-fold Increase [Group 3B (V72_41) vs. Group B_0_1 (V72_41) Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.5</ci_lower_limit>
            <ci_upper_limit>28.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month post booster/first dose of vaccination: Four-fold Increase [Group 3B (V72P10) vs. Group B_0_1 (V72P10) Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.6</ci_lower_limit>
            <ci_upper_limit>31.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month post booster/first dose of vaccination: Four-fold Increase (Group 3B vs. Group B_0_1) Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29.8</ci_lower_limit>
            <ci_upper_limit>45.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month post booster/first dose of vaccination: Four-fold Increase [Group 3B (V72_41) vs. Group B_0_1 (V72_41) Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>43.5</ci_lower_limit>
            <ci_upper_limit>64.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month post booster/first dose of vaccination: Four-fold Increase [Group 3B (V72P10) vs. Group B_0_1 (V72P10) Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.9</ci_lower_limit>
            <ci_upper_limit>35.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month post booster/first dose of vaccination: Four-fold Increase (Group 3B vs. Group B_0_1) Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.7</ci_lower_limit>
            <ci_upper_limit>30.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month post booster/first dose of vaccination: Four-fold Increase [Group 3B (V72_41) vs. Group B_0_1 (V72_41) Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.2</ci_lower_limit>
            <ci_upper_limit>35.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month post booster/first dose of vaccination: Four-fold Increase [Group 3B (V72P10) vs. Group B_0_1 (V72P10) Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.6</ci_lower_limit>
            <ci_upper_limit>32.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA ≥1:5 After Booster Dose/Second Vaccination of rMenB+OMV NZ</title>
        <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713. On day 1, subjects in the Group B_0_1 were to be randomized into 2 different blood draw schedules according to a 1:1 ratio : 2 blood samples at different time points:
Group B_0_1_1: blood draws at 3 and 30 days after the second dose. Group B_0_1_2: blood draws at 7 and 30 days after the second dose.</description>
        <time_frame>Group 3B: 3, 7 and 30 days after third dose booster; Group B_0_1: At 3 (group B_0_1_1 only), 7 (sub-group B_0_1_2 only) and 30 days post-second dose.&quot;</time_frame>
        <population>Analysis was performed on the PPS kinetics which included all subjects who correctly received the vaccination at day 1/ day 1 &amp; day 31 (naive subjects) &amp; provided evaluable immunogenicity result at all of days 4, 8 &amp; 31 (for follow-on subjects) or at all of days 34,38 and 61 (naive subjects).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B (V72_41)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1-month schedule in study V72_41 (NCT0142384) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72_41, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group 3B (V72P10)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72P10, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O3">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O4">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O5">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O6">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥1:5 After Booster Dose/Second Vaccination of rMenB+OMV NZ</title>
          <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713. On day 1, subjects in the Group B_0_1 were to be randomized into 2 different blood draw schedules according to a 1:1 ratio : 2 blood samples at different time points:
Group B_0_1_1: blood draws at 3 and 30 days after the second dose. Group B_0_1_2: blood draws at 7 and 30 days after the second dose.</description>
          <population>Analysis was performed on the PPS kinetics which included all subjects who correctly received the vaccination at day 1/ day 1 &amp; day 31 (naive subjects) &amp; provided evaluable immunogenicity result at all of days 4, 8 &amp; 31 (for follow-on subjects) or at all of days 34,38 and 61 (naive subjects).</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="242"/>
                <count group_id="O4" value="94"/>
                <count group_id="O5" value="109"/>
                <count group_id="O6" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 3 days post vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="242"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="20.9" upper_limit="37.0"/>
                    <measurement group_id="O2" value="46" lower_limit="36.1" upper_limit="55.2"/>
                    <measurement group_id="O3" value="36" lower_limit="30.3" upper_limit="42.8"/>
                    <measurement group_id="O4" value="74" lower_limit="59.7" upper_limit="85.4"/>
                    <measurement group_id="O5" value="85" lower_limit="73.3" upper_limit="93.5"/>
                    <measurement group_id="O6" value="80" lower_limit="71.1" upper_limit="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 7 days post vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="242"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="92.3" upper_limit="99.2"/>
                    <measurement group_id="O2" value="99" lower_limit="95.1" upper_limit="99.98"/>
                    <measurement group_id="O3" value="98" lower_limit="95.2" upper_limit="99.3"/>
                    <measurement group_id="O4" value="100" lower_limit="92.0" upper_limit="100.0"/>
                    <measurement group_id="O5" value="98" lower_limit="90.1" upper_limit="99.95"/>
                    <measurement group_id="O6" value="99" lower_limit="94.4" upper_limit="99.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 1 month post vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="242"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="93.4" upper_limit="99.52"/>
                    <measurement group_id="O2" value="100" lower_limit="96.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99" lower_limit="96.4" upper_limit="99.74"/>
                    <measurement group_id="O4" value="99" lower_limit="94.2" upper_limit="99.97"/>
                    <measurement group_id="O5" value="99" lower_limit="95.0" upper_limit="99.98"/>
                    <measurement group_id="O6" value="99" lower_limit="96.5" upper_limit="99.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99- 3 days post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="185"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="68.4" upper_limit="85.3"/>
                    <measurement group_id="O2" value="79" lower_limit="68.9" upper_limit="87.4"/>
                    <measurement group_id="O3" value="78" lower_limit="71.7" upper_limit="84.1"/>
                    <measurement group_id="O4" value="80" lower_limit="64.7" upper_limit="90.2"/>
                    <measurement group_id="O5" value="86" lower_limit="71.5" upper_limit="94.6"/>
                    <measurement group_id="O6" value="83" lower_limit="72.9" upper_limit="89.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99- 7 days post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="185"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100" lower_limit="95.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100" lower_limit="98.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100" lower_limit="91.2" upper_limit="100.0"/>
                    <measurement group_id="O5" value="98" lower_limit="88.9" upper_limit="99.95"/>
                    <measurement group_id="O6" value="99" lower_limit="93.8" upper_limit="99.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99- 1 month post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="185"/>
                    <count group_id="O4" value="84"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="174"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100" lower_limit="95.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100" lower_limit="98.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O5" value="98" lower_limit="92.2" upper_limit="99.73"/>
                    <measurement group_id="O6" value="99" lower_limit="95.9" upper_limit="99.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254- 3 days post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="233"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="6.0" upper_limit="17.4"/>
                    <measurement group_id="O2" value="26" lower_limit="18.0" upper_limit="35.8"/>
                    <measurement group_id="O3" value="18" lower_limit="12.9" upper_limit="23.1"/>
                    <measurement group_id="O4" value="28" lower_limit="16.2" upper_limit="42.5"/>
                    <measurement group_id="O5" value="58" lower_limit="44.1" upper_limit="71.3"/>
                    <measurement group_id="O6" value="44" lower_limit="34.1" upper_limit="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254- 7 days post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="233"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="61.3" upper_limit="77.7"/>
                    <measurement group_id="O2" value="79" lower_limit="69.5" upper_limit="86.1"/>
                    <measurement group_id="O3" value="74" lower_limit="67.7" upper_limit="79.3"/>
                    <measurement group_id="O4" value="77" lower_limit="62.2" upper_limit="88.5"/>
                    <measurement group_id="O5" value="80" lower_limit="66.5" upper_limit="89.4"/>
                    <measurement group_id="O6" value="79" lower_limit="69.1" upper_limit="86.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254- 1 month post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="233"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="85.4" upper_limit="95.7"/>
                    <measurement group_id="O2" value="94" lower_limit="87.8" upper_limit="97.8"/>
                    <measurement group_id="O3" value="93" lower_limit="88.6" upper_limit="95.7"/>
                    <measurement group_id="O4" value="78" lower_limit="67.9" upper_limit="85.6"/>
                    <measurement group_id="O5" value="75" lower_limit="66.0" upper_limit="83.0"/>
                    <measurement group_id="O6" value="76" lower_limit="69.9" upper_limit="82.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713- 3 days post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="241"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="62.7" upper_limit="78.9"/>
                    <measurement group_id="O2" value="86" lower_limit="77.8" upper_limit="91.6"/>
                    <measurement group_id="O3" value="78" lower_limit="72.2" upper_limit="83.1"/>
                    <measurement group_id="O4" value="76" lower_limit="61.8" upper_limit="86.9"/>
                    <measurement group_id="O5" value="87" lower_limit="75.5" upper_limit="94.7"/>
                    <measurement group_id="O6" value="82" lower_limit="73.2" upper_limit="88.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713- 7 days post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="241"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="93.4" upper_limit="99.52"/>
                    <measurement group_id="O2" value="97" lower_limit="92.4" upper_limit="99.4"/>
                    <measurement group_id="O3" value="98" lower_limit="94.7" upper_limit="99.1"/>
                    <measurement group_id="O4" value="95" lower_limit="84.5" upper_limit="99.4"/>
                    <measurement group_id="O5" value="96" lower_limit="87.3" upper_limit="99.55"/>
                    <measurement group_id="O6" value="96" lower_limit="89.9" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713- 1 month post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="241"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95.8" upper_limit="99.98"/>
                    <measurement group_id="O2" value="99" lower_limit="95.1" upper_limit="99.98"/>
                    <measurement group_id="O3" value="99" lower_limit="97.0" upper_limit="99.90"/>
                    <measurement group_id="O4" value="90" lower_limit="82.6" upper_limit="95.5"/>
                    <measurement group_id="O5" value="95" lower_limit="89.6" upper_limit="98.5"/>
                    <measurement group_id="O6" value="93" lower_limit="88.7" upper_limit="96.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B vs Day 34 Group B_0_1 (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.7</ci_lower_limit>
            <ci_upper_limit>-33.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B vs Day 38 Group B_0_1 (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B vs Day 61 Group B_0_1 (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72_41) vs Day 34 Group B_0_1 (V72_41) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.4</ci_lower_limit>
            <ci_upper_limit>-29.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72_41) vs Day 38 Group B_0_1 (V72_41) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.7</ci_lower_limit>
            <ci_upper_limit>5.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72_41) vs Day 61 Group B_0_1 (V72_41) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.7</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72P10) vs Day 34 Group B_0_1 (V72P10) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>-40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.8</ci_lower_limit>
            <ci_upper_limit>-25.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72P10) vs Day 38 Group B_0_1 (V72P10) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>9.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72P10) vs Day 61 Group B_0_1 (V72P10) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B vs Day 34 Group B_0_1 (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.6</ci_lower_limit>
            <ci_upper_limit>6.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B vs Day 38 Group B_0_1 (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>6.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B vs Day 61 Group B_0_1 (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72_41) vs Day 34 Group B_0_1 (V72_41) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.1</ci_lower_limit>
            <ci_upper_limit>14.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72_41) vs Day 38 Group B_0_1 (V72_41) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>8.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72_41) vs Day 61 Group B_0_1(V72_41) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72P10) vs Day 34 Group B_0_1 (V72P10) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>-6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.4</ci_lower_limit>
            <ci_upper_limit>9.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72P10) vs Day 38 Group B_0_1 (V72P10) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>11.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72P10) vs Day 61 Group B_0_1 (V72P10) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>7.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B vs Day 34 Group B_0_1 (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.9</ci_lower_limit>
            <ci_upper_limit>-15.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B vs Day 38 Group B_0_1 (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.1</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B vs Day 61 Group B_0_1 (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.8</ci_lower_limit>
            <ci_upper_limit>23.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72_41) vs Day 34 Group B_0_1 (V72_41) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.8</ci_lower_limit>
            <ci_upper_limit>-4.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72_41) vs Day 38 Group B_0_1 (V72_41) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.6</ci_lower_limit>
            <ci_upper_limit>8.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72_41) vs Day 61 Group B_0_1 (V72_41) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.6</ci_lower_limit>
            <ci_upper_limit>24.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72P10) vs Day 34 Group B_0_1 (V72P10) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.7</ci_lower_limit>
            <ci_upper_limit>-16.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72P10) vs Day 38 Group B_0_1 (V72P10) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.6</ci_lower_limit>
            <ci_upper_limit>13.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72P10) vs Day 61 Group B_0_1 (V72P10) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.7</ci_lower_limit>
            <ci_upper_limit>28.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B vs Day 34 Group B_0_1 (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.4</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B vs Day 38 Group B_0_1 (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>7.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B vs Day 61 Group B_0_1 (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.8</ci_lower_limit>
            <ci_upper_limit>10.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72_41) vs Day 34 Group B_0_1 (V72_41) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.8</ci_lower_limit>
            <ci_upper_limit>10.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72_41) vs Day 38 Group B_0_1 (V72_41) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>13.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72_41) vs Day 61 Group B_0_1 (V72_41) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.7</ci_lower_limit>
            <ci_upper_limit>16.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72P10) vs Day 34 Group B_0_1 (V72P10) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.8</ci_lower_limit>
            <ci_upper_limit>11.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72_41) vs Day 38 Group B_0_1 (V72_41) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72P10) vs Day 61 Group B_0_1 (V72P10) (1 month days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA ≥1:8 After Booster Dose/Second Vaccination of rMenB+OMV NZ</title>
        <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713. On day 1, subjects in the Group B_0_1 were to be randomized into 2 different blood draw schedules according to a 1:1 ratio : 2 blood samples at different time points:
Group B_0_1_1: blood draws at 3 and 30 days after the second dose. Group B_0_1_2: blood draws at 7 and 30 days after the second dose.</description>
        <time_frame>Group 3B: 3, 7 and 30 days after third dose booster; Group B_0_1: At 3 (group B_0_1_1 only), 7 (sub-group B_0_1_2 only) and 30 days post-second dose.</time_frame>
        <population>Analysis was performed on PPS kinetics which included all subjects who had no protocol deviations/any other reason defined prior to analysis, leading to exclusion &amp; correctly received the vaccination at day 1/day 31 &amp; day 1 &amp; provided evaluable immunogenicity result at all of days 4, 8 &amp; 31 (follow-on subjects)or at all of days 34, 38 &amp; 61(naive)</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B (V72_41)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1-month schedule in study V72_41 (NCT0142384) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72_41, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group 3B (V72P10)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72P10, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O3">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O4">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O5">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O6">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥1:8 After Booster Dose/Second Vaccination of rMenB+OMV NZ</title>
          <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713. On day 1, subjects in the Group B_0_1 were to be randomized into 2 different blood draw schedules according to a 1:1 ratio : 2 blood samples at different time points:
Group B_0_1_1: blood draws at 3 and 30 days after the second dose. Group B_0_1_2: blood draws at 7 and 30 days after the second dose.</description>
          <population>Analysis was performed on PPS kinetics which included all subjects who had no protocol deviations/any other reason defined prior to analysis, leading to exclusion &amp; correctly received the vaccination at day 1/day 31 &amp; day 1 &amp; provided evaluable immunogenicity result at all of days 4, 8 &amp; 31 (follow-on subjects)or at all of days 34, 38 &amp; 61(naive)</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="242"/>
                <count group_id="O4" value="94"/>
                <count group_id="O5" value="109"/>
                <count group_id="O6" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 3 days post vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="242"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="15.5" upper_limit="30.4"/>
                    <measurement group_id="O2" value="39" lower_limit="30.2" upper_limit="49.0"/>
                    <measurement group_id="O3" value="30" lower_limit="24.5" upper_limit="36.4"/>
                    <measurement group_id="O4" value="70" lower_limit="55.4" upper_limit="82.1"/>
                    <measurement group_id="O5" value="80" lower_limit="67.0" upper_limit="89.6"/>
                    <measurement group_id="O6" value="75" lower_limit="65.9" upper_limit="83.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 7 days post vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="242"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="89.2" upper_limit="97.8"/>
                    <measurement group_id="O2" value="98" lower_limit="93.7" upper_limit="99.78"/>
                    <measurement group_id="O3" value="96" lower_limit="93.1" upper_limit="98.3"/>
                    <measurement group_id="O4" value="95" lower_limit="84.5" upper_limit="99.4"/>
                    <measurement group_id="O5" value="98" lower_limit="90.1" upper_limit="99.95"/>
                    <measurement group_id="O6" value="97" lower_limit="91.3" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 1 month post vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="242"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="93.4" upper_limit="99.52"/>
                    <measurement group_id="O2" value="100" lower_limit="96.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99" lower_limit="96.4" upper_limit="99.74"/>
                    <measurement group_id="O4" value="99" lower_limit="94.2" upper_limit="99.97"/>
                    <measurement group_id="O5" value="97" lower_limit="92.2" upper_limit="99.4"/>
                    <measurement group_id="O6" value="98" lower_limit="95.0" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99- 3 days post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="185"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="64.2" upper_limit="82.0"/>
                    <measurement group_id="O2" value="79" lower_limit="68.9" upper_limit="87.4"/>
                    <measurement group_id="O3" value="76" lower_limit="69.4" upper_limit="82.2"/>
                    <measurement group_id="O4" value="80" lower_limit="64.7" upper_limit="90.2"/>
                    <measurement group_id="O5" value="86" lower_limit="71.5" upper_limit="94.6"/>
                    <measurement group_id="O6" value="83" lower_limit="72.9" upper_limit="89.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99- 7 days post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="185"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100" lower_limit="95.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100" lower_limit="98.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100" lower_limit="91.2" upper_limit="100.0"/>
                    <measurement group_id="O5" value="98" lower_limit="88.9" upper_limit="99.95"/>
                    <measurement group_id="O6" value="99" lower_limit="93.8" upper_limit="99.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99- 1 month post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="185"/>
                    <count group_id="O4" value="84"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="174"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100" lower_limit="95.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100" lower_limit="98.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O5" value="98" lower_limit="92.2" upper_limit="99.73"/>
                    <measurement group_id="O6" value="99" lower_limit="95.9" upper_limit="99.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254- 3 days post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="233"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="5.4" upper_limit="16.5"/>
                    <measurement group_id="O2" value="23" lower_limit="15.5" upper_limit="32.7"/>
                    <measurement group_id="O3" value="16" lower_limit="11.4" upper_limit="21.2"/>
                    <measurement group_id="O4" value="28" lower_limit="16.2" upper_limit="42.5"/>
                    <measurement group_id="O5" value="55" lower_limit="40.6" upper_limit="68.0"/>
                    <measurement group_id="O6" value="42" lower_limit="32.3" upper_limit="51.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254- 7 days post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="233"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="51.8" upper_limit="69.2"/>
                    <measurement group_id="O2" value="74" lower_limit="64.2" upper_limit="82.0"/>
                    <measurement group_id="O3" value="67" lower_limit="60.1" upper_limit="72.6"/>
                    <measurement group_id="O4" value="68" lower_limit="52.4" upper_limit="81.4"/>
                    <measurement group_id="O5" value="70" lower_limit="56.4" upper_limit="82.0"/>
                    <measurement group_id="O6" value="69" lower_limit="59.3" upper_limit="78.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254- 1 month post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="233"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="77.2" upper_limit="90.3"/>
                    <measurement group_id="O2" value="91" lower_limit="84.1" upper_limit="95.9"/>
                    <measurement group_id="O3" value="88" lower_limit="82.6" upper_limit="91.5"/>
                    <measurement group_id="O4" value="65" lower_limit="54.4" upper_limit="74.5"/>
                    <measurement group_id="O5" value="69" lower_limit="59.2" upper_limit="77.3"/>
                    <measurement group_id="O6" value="67" lower_limit="60.1" upper_limit="73.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713- 3 days post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="241"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="53.1" upper_limit="70.4"/>
                    <measurement group_id="O2" value="79" lower_limit="69.8" upper_limit="85.8"/>
                    <measurement group_id="O3" value="70" lower_limit="63.5" upper_limit="75.4"/>
                    <measurement group_id="O4" value="62" lower_limit="47.2" upper_limit="75.3"/>
                    <measurement group_id="O5" value="84" lower_limit="71.2" upper_limit="92.2"/>
                    <measurement group_id="O6" value="73" lower_limit="63.8" upper_limit="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713- 7 days post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="241"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="90.2" upper_limit="98.3"/>
                    <measurement group_id="O2" value="96" lower_limit="89.9" upper_limit="98.5"/>
                    <measurement group_id="O3" value="95" lower_limit="92.0" upper_limit="97.7"/>
                    <measurement group_id="O4" value="93" lower_limit="81.3" upper_limit="98.6"/>
                    <measurement group_id="O5" value="94" lower_limit="84.6" upper_limit="98.8"/>
                    <measurement group_id="O6" value="94" lower_limit="87.1" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713- 1 month post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="241"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94.5" upper_limit="99.81"/>
                    <measurement group_id="O2" value="98" lower_limit="93.7" upper_limit="99.78"/>
                    <measurement group_id="O3" value="98" lower_limit="95.8" upper_limit="99.55"/>
                    <measurement group_id="O4" value="86" lower_limit="77.5" upper_limit="92.4"/>
                    <measurement group_id="O5" value="94" lower_limit="87.2" upper_limit="97.4"/>
                    <measurement group_id="O6" value="90" lower_limit="85.2" upper_limit="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B vs Day 34 Group B_0_1 (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.4</ci_lower_limit>
            <ci_upper_limit>-34.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B vs Day 38 Group B_0_1 (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>5.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B vs Day 61 Group B_0_1 (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72_41) vs Day 34 Group B_0_1 (V72_41) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.8</ci_lower_limit>
            <ci_upper_limit>-32.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72_41) vs Day 38 Group B_0_1 (V72_41) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72_41) vs Day 61 Group B_0_1 (V72_41) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.7</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72P10) vs Day 34 Group B_0_1 (V72P10) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.3</ci_lower_limit>
            <ci_upper_limit>-25.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72_41) vs Day 38 Group B_0_1 (V72_41) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>8.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72P10) vs Day 61 Group B_0_1 (V72P10) (1 month days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>7.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B vs Day 34 Group B_0_1 (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.9</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B vs Day 38 Group B_0_1 (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>6.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B vs Day 61 Group B_0_1 (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72_41) vs Day 34 Group B_0_1 (V72_41) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.2</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72_41) vs Day 38 Group B_0_1 (V72_41) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>8.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72_41) vs Day 61 Group B_0_1 (V72_41) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72P10) vs Day 34 Group B_0_1 (V72P10) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.4</ci_lower_limit>
            <ci_upper_limit>9.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72P10) vs Day 38 Group B_0_1 (V72P10) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>11.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72P10) vs Day 61 Group B_0_1 (V72P10) (1 month days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>7.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B vs Day 34 Group B_0_1 (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.6</ci_lower_limit>
            <ci_upper_limit>-15.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B vs Day 38 Group B_0_1 (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.3</ci_lower_limit>
            <ci_upper_limit>8.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B vs Day 61 Group B_0_1 (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.8</ci_lower_limit>
            <ci_upper_limit>28.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72_41) vs Day 34 Group B_0_1 (V72_41) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.5</ci_lower_limit>
            <ci_upper_limit>-5.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72_41) vs Day 38 Group B_0_1 (V72_41) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.3</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72_41) vs Day 61 Group B_0_1 (V72_41) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.4</ci_lower_limit>
            <ci_upper_limit>31.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72P10) vs Day 34 Group B_0_1 (V72P10) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.0</ci_lower_limit>
            <ci_upper_limit>-15.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72P10) vs Day 38 Group B_0_1 (V72P10) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.8</ci_lower_limit>
            <ci_upper_limit>18.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72P10) vs Day 61 Group B_0_1 (V72P10) (1 month days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.1</ci_lower_limit>
            <ci_upper_limit>32.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B vs Day 34 Group B_0_1 (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.4</ci_lower_limit>
            <ci_upper_limit>7.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B vs Day 38 Group B_0_1 (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>8.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B vs Day 61 Group B_0_1 (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.2</ci_lower_limit>
            <ci_upper_limit>13.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72_41) vs Day 34 Group B_0_1 (V72_41) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.1</ci_lower_limit>
            <ci_upper_limit>16.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72_41) vs Day 38 Group B_0_1 (V72_41) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>13.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72_41) vs Day 61 Group B_0_1 (V72_41) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.9</ci_lower_limit>
            <ci_upper_limit>20.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72P10) vs Day 34 Group B_0_1 (V72P10) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.7</ci_lower_limit>
            <ci_upper_limit>8.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72P10) vs Day 38 Group B_0_1 (V72P10) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.7</ci_lower_limit>
            <ci_upper_limit>11.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72P10) vs Day 61 Group B_0_1 (V72P10) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>11.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA ≥1:16 After Booster Dose/Second Vaccination of rMenB+OMV NZ</title>
        <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713. On day 1, subjects in the Group B_0_1 were to be randomized into 2 different blood draw schedules according to a 1:1 ratio : 2 blood samples at different time points:
Group B_0_1_1: blood draws at 3 and 30 days after the second dose. Group B_0_1_2: blood draws at 7 and 30 days after the second dose</description>
        <time_frame>Group 3B: 3, 7 and 30 days after third dose booster; Group B_0_1: At 3 (group B_0_1_1 only), 7 (sub-group B_0_1_2 only) and 30 days post-second dose</time_frame>
        <population>Analysis was performed on PPS kinetics which included all subjects who had no protocol deviations/any other reason defined prior to analysis, leading to exclusion &amp; correctly received the vaccination at day 1/day 31 &amp; day 1 &amp; provided evaluable immunogenicity result at all of days 4, 8 &amp; 31 (follow-on subjects)or at all of days 34, 38 &amp; 61(naive)</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B (V72_41)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1-month schedule in study V72_41 (NCT0142384) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72_41, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group 3B (V72P10)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72P10, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O3">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O4">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O5">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O6">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥1:16 After Booster Dose/Second Vaccination of rMenB+OMV NZ</title>
          <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713. On day 1, subjects in the Group B_0_1 were to be randomized into 2 different blood draw schedules according to a 1:1 ratio : 2 blood samples at different time points:
Group B_0_1_1: blood draws at 3 and 30 days after the second dose. Group B_0_1_2: blood draws at 7 and 30 days after the second dose</description>
          <population>Analysis was performed on PPS kinetics which included all subjects who had no protocol deviations/any other reason defined prior to analysis, leading to exclusion &amp; correctly received the vaccination at day 1/day 31 &amp; day 1 &amp; provided evaluable immunogenicity result at all of days 4, 8 &amp; 31 (follow-on subjects)or at all of days 34, 38 &amp; 61(naive)</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="242"/>
                <count group_id="O4" value="94"/>
                <count group_id="O5" value="109"/>
                <count group_id="O6" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 3 days post vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="242"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="7.8" upper_limit="20.1"/>
                    <measurement group_id="O2" value="29" lower_limit="21.2" upper_limit="38.8"/>
                    <measurement group_id="O3" value="21" lower_limit="15.7" upper_limit="26.3"/>
                    <measurement group_id="O4" value="40" lower_limit="26.4" upper_limit="54.8"/>
                    <measurement group_id="O5" value="60" lower_limit="45.9" upper_limit="73.0"/>
                    <measurement group_id="O6" value="50" lower_limit="40.5" upper_limit="60.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 7 days post vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="242"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="85.4" upper_limit="95.7"/>
                    <measurement group_id="O2" value="98" lower_limit="93.7" upper_limit="99.78"/>
                    <measurement group_id="O3" value="95" lower_limit="91.0" upper_limit="97.1"/>
                    <measurement group_id="O4" value="89" lower_limit="75.4" upper_limit="96.2"/>
                    <measurement group_id="O5" value="94" lower_limit="84.6" upper_limit="98.8"/>
                    <measurement group_id="O6" value="92" lower_limit="84.5" upper_limit="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 1 month post vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="242"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="93.4" upper_limit="99.52"/>
                    <measurement group_id="O2" value="100" lower_limit="96.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99" lower_limit="96.4" upper_limit="99.74"/>
                    <measurement group_id="O4" value="90" lower_limit="82.6" upper_limit="95.5"/>
                    <measurement group_id="O5" value="92" lower_limit="84.9" upper_limit="96.2"/>
                    <measurement group_id="O6" value="91" lower_limit="86.3" upper_limit="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99- 3 days post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="185"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="59.1" upper_limit="77.7"/>
                    <measurement group_id="O2" value="72" lower_limit="60.9" upper_limit="81.3"/>
                    <measurement group_id="O3" value="70" lower_limit="63.1" upper_limit="76.8"/>
                    <measurement group_id="O4" value="75" lower_limit="59.7" upper_limit="86.8"/>
                    <measurement group_id="O5" value="76" lower_limit="60.5" upper_limit="87.9"/>
                    <measurement group_id="O6" value="76" lower_limit="65.1" upper_limit="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99- 7 days post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="185"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.5" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95.6" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100" lower_limit="91.2" upper_limit="100"/>
                    <measurement group_id="O5" value="98" lower_limit="88.9" upper_limit="99.95"/>
                    <measurement group_id="O6" value="99" lower_limit="93.8" upper_limit="99.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99- 1 month post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="185"/>
                    <count group_id="O4" value="84"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="174"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100" lower_limit="95.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100" lower_limit="98.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O5" value="97" lower_limit="90.6" upper_limit="99.3"/>
                    <measurement group_id="O6" value="98" lower_limit="95.0" upper_limit="99.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254- 3 days post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="233"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2.2" upper_limit="10.8"/>
                    <measurement group_id="O2" value="15" lower_limit="8.4" upper_limit="22.9"/>
                    <measurement group_id="O3" value="9" lower_limit="6.0" upper_limit="13.9"/>
                    <measurement group_id="O4" value="18" lower_limit="8.6" upper_limit="31.4"/>
                    <measurement group_id="O5" value="40" lower_limit="27.0" upper_limit="54.1"/>
                    <measurement group_id="O6" value="30" lower_limit="21.0" upper_limit="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254- 7 days post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="233"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="32.2" upper_limit="49.7"/>
                    <measurement group_id="O2" value="64" lower_limit="54.0" upper_limit="73.3"/>
                    <measurement group_id="O3" value="51" lower_limit="44.5" upper_limit="57.7"/>
                    <measurement group_id="O4" value="41" lower_limit="26.3" upper_limit="56.8"/>
                    <measurement group_id="O5" value="52" lower_limit="37.8" upper_limit="65.7"/>
                    <measurement group_id="O6" value="47" lower_limit="36.8" upper_limit="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254- 1 month post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="233"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="65.4" upper_limit="81.2"/>
                    <measurement group_id="O2" value="89" lower_limit="81.7" upper_limit="94.5"/>
                    <measurement group_id="O3" value="81" lower_limit="75.0" upper_limit="85.6"/>
                    <measurement group_id="O4" value="40" lower_limit="30.4" upper_limit="51.0"/>
                    <measurement group_id="O5" value="56" lower_limit="46.1" upper_limit="65.5"/>
                    <measurement group_id="O6" value="49" lower_limit="41.7" upper_limit="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713- 3 days post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="241"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="39.2" upper_limit="57.0"/>
                    <measurement group_id="O2" value="71" lower_limit="61.2" upper_limit="78.8"/>
                    <measurement group_id="O3" value="59" lower_limit="52.0" upper_limit="64.8"/>
                    <measurement group_id="O4" value="50" lower_limit="35.5" upper_limit="64.5"/>
                    <measurement group_id="O5" value="76" lower_limit="63.0" upper_limit="86.8"/>
                    <measurement group_id="O6" value="64" lower_limit="53.9" upper_limit="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713- 7 days post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="241"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="78.0" upper_limit="90.9"/>
                    <measurement group_id="O2" value="91" lower_limit="84.2" upper_limit="95.6"/>
                    <measurement group_id="O3" value="88" lower_limit="83.2" upper_limit="91.8"/>
                    <measurement group_id="O4" value="84" lower_limit="69.9" upper_limit="93.4"/>
                    <measurement group_id="O5" value="91" lower_limit="79.7" upper_limit="96.9"/>
                    <measurement group_id="O6" value="88" lower_limit="79.6" upper_limit="93.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713- 1 month post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="241"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="87.2" upper_limit="96.8"/>
                    <measurement group_id="O2" value="97" lower_limit="92.4" upper_limit="99.4"/>
                    <measurement group_id="O3" value="95" lower_limit="91.5" upper_limit="97.4"/>
                    <measurement group_id="O4" value="76" lower_limit="65.6" upper_limit="83.8"/>
                    <measurement group_id="O5" value="92" lower_limit="84.9" upper_limit="96.2"/>
                    <measurement group_id="O6" value="84" lower_limit="78.5" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B vs Day 34 Group B_0_1 (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.4</ci_lower_limit>
            <ci_upper_limit>-19.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B vs Day 38 Group B_0_1 (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B vs Day 61 Group B_0_1 (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.9</ci_lower_limit>
            <ci_upper_limit>12.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72_41) vs Day 34 Group B_0_1 (V72_41) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.8</ci_lower_limit>
            <ci_upper_limit>-12.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72_41) vs Day 38 Group B_0_1 (V72_41) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.0</ci_lower_limit>
            <ci_upper_limit>16.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72_41) vs Day 61 Group B_0_1 (V72_41) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4</ci_lower_limit>
            <ci_upper_limit>15.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72P10) vs Day 34 Group B_0_1 (V72P10) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.1</ci_lower_limit>
            <ci_upper_limit>-14.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72P10) vs Day 38 Group B_0_1 (V72P10) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9</ci_lower_limit>
            <ci_upper_limit>13.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72_41) vs Day 61 Group B_0_1 (V72_41) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.4</ci_lower_limit>
            <ci_upper_limit>15.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B vs Day 34 Group B_0_1 (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.0</ci_lower_limit>
            <ci_upper_limit>6.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B vs Day 38 Group B_0_1 (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>6.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B vs Day 61 Group B_0_1 (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72_41) vs Day 34 Group B_0_1 (V72_41) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.5</ci_lower_limit>
            <ci_upper_limit>10.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72_41) vs Day 38 Group B_0_1 (V72_41) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>8.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72_41) vs Day 61 Group B_0_1 (V72_41) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72P10) vs Day 34 Group B_0_1 (V72P10) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.4</ci_lower_limit>
            <ci_upper_limit>13.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72P10) vs Day 38 Group B_0_1 (V72P10) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>11.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72P10) vs Day 61 Group B_0_1 (V72P10) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>9.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B vs Day 34 Group B_0_1 (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.0</ci_lower_limit>
            <ci_upper_limit>-11.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B vs Day 38 Group B_0_1 (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.6</ci_lower_limit>
            <ci_upper_limit>15.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B vs Day 61 Group B_0_1 (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.2</ci_lower_limit>
            <ci_upper_limit>40.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72_41) vs Day 34 Group B_0_1 (V72_41) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.9</ci_lower_limit>
            <ci_upper_limit>-3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72_41) vs Day 38 Group B_0_1 (V72_41) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.1</ci_lower_limit>
            <ci_upper_limit>15.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72_41) vs Day 61 Group B_0_1 (V72_41) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.5</ci_lower_limit>
            <ci_upper_limit>45.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72P10) vs Day 34 Group B_0_1 (V72P10) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.1</ci_lower_limit>
            <ci_upper_limit>-11.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72P10) vs Day 38 Group B_0_1 (V72P10) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>28.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72P10) vs Day 61 Group B_0_1 (V72P10) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.0</ci_lower_limit>
            <ci_upper_limit>44.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B vs Day 34 Group B_0_1 (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.0</ci_lower_limit>
            <ci_upper_limit>6.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B vs Day 38 Group B_0_1 (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>8.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B vs Day 61 Group B_0_1 (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.3</ci_lower_limit>
            <ci_upper_limit>16.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72_41) vs Day 34 Group B_0_1 (V72_41) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.0</ci_lower_limit>
            <ci_upper_limit>14.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72_41) vs Day 38 Group B_0_1 (V72_41) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.7</ci_lower_limit>
            <ci_upper_limit>15.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72_41) vs Day 61 Group B_0_1 (V72_41) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.2</ci_lower_limit>
            <ci_upper_limit>27.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 4 Group 3B (V72P10) vs Day 34 Group B_0_1 (V72P10) (3 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.1</ci_lower_limit>
            <ci_upper_limit>9.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 8 Group 3B (V72P10) vs Day 38 Group B_0_1 (V72P10) (7 days after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.4</ci_lower_limit>
            <ci_upper_limit>11.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine comparison at Day 31 Group 3B (V72P10) vs Day 61 Group B_0_1 (V72P10) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>12.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA Geometric Mean Titers Prior to Booster/Second Dose of Vaccination &amp; Post Booster/Second Dose of Vaccination.</title>
        <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713. On day 1, subjects in the Group B_0_1 were to be randomized into 2 different blood draw schedules according to a 1:1 ratio : 2 blood samples at different time points:
Group B_0_1_1: blood draws at 3 and 30 days after the second dose. Group B_0_1_2: blood draws at 7 and 30 days after the second dose.</description>
        <time_frame>Group 3B: Day 1 (pre-booster dose) and 3, 7 and 30 days after third dose booster; Group B_0_1: Pre 2nd dose and at 3 (group B_0_1_1 only), 7 (group B_0_1_2 only) and 30 days post second dose.</time_frame>
        <population>Analysis was performed on PPS kinetics which included all subjects who had no protocol deviations/any other reason defined prior to analysis, leading to exclusion &amp; correctly received the vaccination at day 1/day 31 &amp; day 1 &amp; provided evaluable immunogenicity result at all of days 4, 8 &amp; 31 (follow-on subjects)or at all of days 34, 38 &amp; 61(naive)</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B (V72_41)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1-month schedule in study V72_41 (NCT0142384) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72_41, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group 3B (V72P10)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72P10, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O3">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O4">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O5">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O6">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA Geometric Mean Titers Prior to Booster/Second Dose of Vaccination &amp; Post Booster/Second Dose of Vaccination.</title>
          <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713. On day 1, subjects in the Group B_0_1 were to be randomized into 2 different blood draw schedules according to a 1:1 ratio : 2 blood samples at different time points:
Group B_0_1_1: blood draws at 3 and 30 days after the second dose. Group B_0_1_2: blood draws at 7 and 30 days after the second dose.</description>
          <population>Analysis was performed on PPS kinetics which included all subjects who had no protocol deviations/any other reason defined prior to analysis, leading to exclusion &amp; correctly received the vaccination at day 1/day 31 &amp; day 1 &amp; provided evaluable immunogenicity result at all of days 4, 8 &amp; 31 (follow-on subjects)or at all of days 34, 38 &amp; 61(naive)</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="242"/>
                <count group_id="O4" value="94"/>
                <count group_id="O5" value="109"/>
                <count group_id="O6" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 - pre-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="242"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" lower_limit="1.86" upper_limit="3.13"/>
                    <measurement group_id="O2" value="4.61" lower_limit="3.34" upper_limit="6.38"/>
                    <measurement group_id="O3" value="2.99" lower_limit="2.41" upper_limit="3.70"/>
                    <measurement group_id="O4" value="14" lower_limit="10" upper_limit="19"/>
                    <measurement group_id="O5" value="27" lower_limit="19" upper_limit="37"/>
                    <measurement group_id="O6" value="17" lower_limit="14" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 - 3 days post-vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="242"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" lower_limit="2.06" upper_limit="3.48"/>
                    <measurement group_id="O2" value="4.57" lower_limit="3.38" upper_limit="6.18"/>
                    <measurement group_id="O3" value="3.20" lower_limit="2.60" upper_limit="3.94"/>
                    <measurement group_id="O4" value="14" lower_limit="9.55" upper_limit="22"/>
                    <measurement group_id="O5" value="24" lower_limit="16" upper_limit="37"/>
                    <measurement group_id="O6" value="17" lower_limit="13" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 - 7 days post-vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="242"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="77" upper_limit="123"/>
                    <measurement group_id="O2" value="153" lower_limit="123" upper_limit="191"/>
                    <measurement group_id="O3" value="115" lower_limit="98" upper_limit="136"/>
                    <measurement group_id="O4" value="62" lower_limit="42" upper_limit="90"/>
                    <measurement group_id="O5" value="60" lower_limit="44" upper_limit="83"/>
                    <measurement group_id="O6" value="57" lower_limit="44" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 - 1 month post-vacc.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="242"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157" lower_limit="127" upper_limit="193"/>
                    <measurement group_id="O2" value="285" lower_limit="234" upper_limit="345"/>
                    <measurement group_id="O3" value="196" lower_limit="170" upper_limit="228"/>
                    <measurement group_id="O4" value="57" lower_limit="45" upper_limit="73"/>
                    <measurement group_id="O5" value="64" lower_limit="52" upper_limit="78"/>
                    <measurement group_id="O6" value="56" lower_limit="48" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99- pre-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="175"/>
                    <count group_id="O4" value="82"/>
                    <count group_id="O5" value="87"/>
                    <count group_id="O6" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="14" upper_limit="29"/>
                    <measurement group_id="O2" value="30" lower_limit="20" upper_limit="47"/>
                    <measurement group_id="O3" value="24" lower_limit="18" upper_limit="32"/>
                    <measurement group_id="O4" value="33" lower_limit="23" upper_limit="50"/>
                    <measurement group_id="O5" value="30" lower_limit="20" upper_limit="44"/>
                    <measurement group_id="O6" value="31" lower_limit="23" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99- 3 days post-vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="185"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="16" upper_limit="34"/>
                    <measurement group_id="O2" value="25" lower_limit="17" upper_limit="35"/>
                    <measurement group_id="O3" value="24" lower_limit="18" upper_limit="31"/>
                    <measurement group_id="O4" value="27" lower_limit="15" upper_limit="49"/>
                    <measurement group_id="O5" value="28" lower_limit="17" upper_limit="47"/>
                    <measurement group_id="O6" value="27" lower_limit="19" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99- 7 days post-vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="185"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1969" lower_limit="1516" upper_limit="2556"/>
                    <measurement group_id="O2" value="1547" lower_limit="1191" upper_limit="2009"/>
                    <measurement group_id="O3" value="1787" lower_limit="1477" upper_limit="2162"/>
                    <measurement group_id="O4" value="294" lower_limit="197" upper_limit="439"/>
                    <measurement group_id="O5" value="365" lower_limit="259" upper_limit="514"/>
                    <measurement group_id="O6" value="337" lower_limit="257" upper_limit="442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99- 1 month post-vacc.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="185"/>
                    <count group_id="O4" value="84"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="174"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2147" lower_limit="1749" upper_limit="2635"/>
                    <measurement group_id="O2" value="1903" lower_limit="1469" upper_limit="2466"/>
                    <measurement group_id="O3" value="2026" lower_limit="1714" upper_limit="2395"/>
                    <measurement group_id="O4" value="224" lower_limit="179" upper_limit="281"/>
                    <measurement group_id="O5" value="276" lower_limit="215" upper_limit="353"/>
                    <measurement group_id="O6" value="248" lower_limit="208" upper_limit="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254- pre-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="231"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="108"/>
                    <count group_id="O6" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" lower_limit="1.06" upper_limit="1.63"/>
                    <measurement group_id="O2" value="2.40" lower_limit="1.72" upper_limit="3.37"/>
                    <measurement group_id="O3" value="1.57" lower_limit="1.29" upper_limit="1.92"/>
                    <measurement group_id="O4" value="3.44" lower_limit="2.66" upper_limit="4.43"/>
                    <measurement group_id="O5" value="9.79" lower_limit="7.07" upper_limit="14"/>
                    <measurement group_id="O6" value="5.11" lower_limit="4.10" upper_limit="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254- 3 days post-vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="233"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" lower_limit="1.15" upper_limit="1.70"/>
                    <measurement group_id="O2" value="2.34" lower_limit="1.72" upper_limit="3.20"/>
                    <measurement group_id="O3" value="1.62" lower_limit="1.35" upper_limit="1.96"/>
                    <measurement group_id="O4" value="2.75" lower_limit="2.02" upper_limit="3.74"/>
                    <measurement group_id="O5" value="8.94" lower_limit="5.84" upper_limit="14"/>
                    <measurement group_id="O6" value="4.45" lower_limit="3.38" upper_limit="5.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254- 7 days post-vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="233"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="7.80" upper_limit="13"/>
                    <measurement group_id="O2" value="18" lower_limit="13" upper_limit="25"/>
                    <measurement group_id="O3" value="12" lower_limit="10" upper_limit="15"/>
                    <measurement group_id="O4" value="11" lower_limit="6.96" upper_limit="17"/>
                    <measurement group_id="O5" value="15" lower_limit="9.79" upper_limit="24"/>
                    <measurement group_id="O6" value="12" lower_limit="8.46" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254- 1 month post-vacc.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="233"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="25" upper_limit="40"/>
                    <measurement group_id="O2" value="44" lower_limit="33" upper_limit="59"/>
                    <measurement group_id="O3" value="35" lower_limit="29" upper_limit="42"/>
                    <measurement group_id="O4" value="12" lower_limit="9.04" upper_limit="16"/>
                    <measurement group_id="O5" value="17" lower_limit="13" upper_limit="23"/>
                    <measurement group_id="O6" value="14" lower_limit="11" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713- pre-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="240"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="202"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="9.76" upper_limit="18"/>
                    <measurement group_id="O2" value="22" lower_limit="16" upper_limit="29"/>
                    <measurement group_id="O3" value="15" lower_limit="12" upper_limit="19"/>
                    <measurement group_id="O4" value="25" lower_limit="18" upper_limit="35"/>
                    <measurement group_id="O5" value="50" lower_limit="38" upper_limit="67"/>
                    <measurement group_id="O6" value="32" lower_limit="25" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713- 3 days post-vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="241"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="9.96" upper_limit="19"/>
                    <measurement group_id="O2" value="24" lower_limit="18" upper_limit="32"/>
                    <measurement group_id="O3" value="16" lower_limit="13" upper_limit="21"/>
                    <measurement group_id="O4" value="18" lower_limit="11" upper_limit="30"/>
                    <measurement group_id="O5" value="37" lower_limit="24" upper_limit="56"/>
                    <measurement group_id="O6" value="23" lower_limit="17" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713- 7 days post-vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="241"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="39" upper_limit="59"/>
                    <measurement group_id="O2" value="68" lower_limit="56" upper_limit="82"/>
                    <measurement group_id="O3" value="54" lower_limit="46" upper_limit="62"/>
                    <measurement group_id="O4" value="42" lower_limit="30" upper_limit="59"/>
                    <measurement group_id="O5" value="56" lower_limit="42" upper_limit="73"/>
                    <measurement group_id="O6" value="45" lower_limit="36" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713- 1 month post-vacc.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="241"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="52" upper_limit="80"/>
                    <measurement group_id="O2" value="116" lower_limit="94" upper_limit="143"/>
                    <measurement group_id="O3" value="78" lower_limit="67" upper_limit="92"/>
                    <measurement group_id="O4" value="34" lower_limit="26" upper_limit="44"/>
                    <measurement group_id="O5" value="61" lower_limit="49" upper_limit="75"/>
                    <measurement group_id="O6" value="41" lower_limit="35" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for H44/76 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison Day 31 Group 3B vs Day 61 Group B_0_1(1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>3.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.85</ci_lower_limit>
            <ci_upper_limit>4.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for H44/76 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison Day 31 Group 3B (V72_41) vs Day 61 Group B_0_1 (V72_41) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>2.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.02</ci_lower_limit>
            <ci_upper_limit>3.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for H44/76 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison Day 31 Group 3B (V72P10) vs Day 61 Group B_0_1 (V72P10) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>4.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.38</ci_lower_limit>
            <ci_upper_limit>5.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for 5/99 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison Day 31 Group 3B vs Day 61 Group B_0_1(1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>8.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.51</ci_lower_limit>
            <ci_upper_limit>10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for 5/99 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison Day 31 Group 3B (V72_41) vs Day 61 Group B_0_1 (V72_41) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>9.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.17</ci_lower_limit>
            <ci_upper_limit>13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for 5/99 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison Day 31 Group 3B (V72P10) vs Day 61 Group B_0_1 (V72P10) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>6.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.82</ci_lower_limit>
            <ci_upper_limit>9.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for NZ98/254 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison Day 31 Group 3B vs Day 61 Group B_0_1(1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>2.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.98</ci_lower_limit>
            <ci_upper_limit>3.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for NZ98/254 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison Day 31 Group 3B (V72_41) vs Day 61 Group B_0_1 (V72_41) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>2.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.89</ci_lower_limit>
            <ci_upper_limit>3.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for NZ98/254 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison Day 31 Group 3B (V72P10) vs Day 61 Group B_0_1 (V72P10) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>2.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.67</ci_lower_limit>
            <ci_upper_limit>3.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for M10713 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison Day 31 Group 3B vs Day 61 Group B_0_1(1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.52</ci_lower_limit>
            <ci_upper_limit>2.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for M10713 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison Day 31 Group 3B (V72_41) vs Day 61 Group B_0_1 (V72_41) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.37</ci_lower_limit>
            <ci_upper_limit>2.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Adjusted geometric mean titers for M10713 indicator strain were obtained by exponentiating (base 10) the least square means and the lower and upper limits of the 95% confidence intervals of the log-transformed titers obtained from an ANOVA estimation adjusting for vaccine group and country.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Vaccine Comparison Day 31 Group 3B (V72P10) vs Day 61 Group B_0_1 (V72P10) (1 month after booster or 2nd dose)</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.41</ci_lower_limit>
            <ci_upper_limit>2.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratios (GMRs) of GMTs After Booster/Second Vaccination Versus Before Booster/Second Vaccination.</title>
        <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713 by calculating the GMRs of GMTs post-vaccination with a booster dose (Group 3B) versus pre-booster dose or second dose (Group B_0_1) of vaccination versus pre second dose.</description>
        <time_frame>Group 3B: Day 1 and 30 days after third dose booster; Group B_0_1: 30 days post-first dose and at 30 days post-second dose</time_frame>
        <population>Analysis was performed on PPS kinetics which included all subjects who had no protocol deviations/any other reason defined prior to analysis, leading to exclusion &amp; correctly received the vaccination at day 1/day 31 &amp; day 1 &amp; provided evaluable immunogenicity result at all of days 4, 8 &amp; 31 (follow-on subjects)or at all of days 34, 38 &amp; 61(naive)</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B (V72_41)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1-month schedule in study V72_41 (NCT0142384) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72_41, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group 3B (V72P10)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72P10, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O3">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O4">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O5">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O6">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratios (GMRs) of GMTs After Booster/Second Vaccination Versus Before Booster/Second Vaccination.</title>
          <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713 by calculating the GMRs of GMTs post-vaccination with a booster dose (Group 3B) versus pre-booster dose or second dose (Group B_0_1) of vaccination versus pre second dose.</description>
          <population>Analysis was performed on PPS kinetics which included all subjects who had no protocol deviations/any other reason defined prior to analysis, leading to exclusion &amp; correctly received the vaccination at day 1/day 31 &amp; day 1 &amp; provided evaluable immunogenicity result at all of days 4, 8 &amp; 31 (follow-on subjects)or at all of days 34, 38 &amp; 61(naive)</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="242"/>
                <count group_id="O4" value="94"/>
                <count group_id="O5" value="109"/>
                <count group_id="O6" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="242"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="49" upper_limit="85"/>
                    <measurement group_id="O2" value="62" lower_limit="49" upper_limit="78"/>
                    <measurement group_id="O3" value="66" lower_limit="55" upper_limit="79"/>
                    <measurement group_id="O4" value="4.21" lower_limit="3.05" upper_limit="5.80"/>
                    <measurement group_id="O5" value="2.37" lower_limit="1.87" upper_limit="3.00"/>
                    <measurement group_id="O6" value="3.27" lower_limit="2.66" upper_limit="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="175"/>
                    <count group_id="O4" value="82"/>
                    <count group_id="O5" value="87"/>
                    <count group_id="O6" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105" lower_limit="76" upper_limit="145"/>
                    <measurement group_id="O2" value="62" lower_limit="41" upper_limit="96"/>
                    <measurement group_id="O3" value="85" lower_limit="65" upper_limit="111"/>
                    <measurement group_id="O4" value="6.86" lower_limit="4.82" upper_limit="9.78"/>
                    <measurement group_id="O5" value="9.09" lower_limit="6.10" upper_limit="14"/>
                    <measurement group_id="O6" value="8.10" lower_limit="6.12" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="231"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="108"/>
                    <count group_id="O6" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="19" upper_limit="30"/>
                    <measurement group_id="O2" value="18" lower_limit="14" upper_limit="24"/>
                    <measurement group_id="O3" value="22" lower_limit="19" upper_limit="27"/>
                    <measurement group_id="O4" value="3.42" lower_limit="2.59" upper_limit="4.51"/>
                    <measurement group_id="O5" value="1.76" lower_limit="1.36" upper_limit="2.29"/>
                    <measurement group_id="O6" value="2.63" lower_limit="2.15" upper_limit="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="240"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="202"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" lower_limit="3.92" upper_limit="6.05"/>
                    <measurement group_id="O2" value="5.30" lower_limit="4.29" upper_limit="6.55"/>
                    <measurement group_id="O3" value="5.07" lower_limit="4.33" upper_limit="5.94"/>
                    <measurement group_id="O4" value="1.36" lower_limit="1.06" upper_limit="1.75"/>
                    <measurement group_id="O5" value="1.20" lower_limit="0.97" upper_limit="1.49"/>
                    <measurement group_id="O6" value="1.27" lower_limit="1.07" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With at Least Four-fold Increase in hSBA Titers Pre-booster/Second Dose Vaccination- Compared to 3, 7 and 30 Days Post- Booster/Second Vaccination</title>
        <description>The percentage of subjects with 4-fold rise at 3, 7, 30 days post-vaccination with a booster dose (follow-on subjects) /second dose (naive subjects) of rMenB+OMV NZ with respect to day 1 (follow-on subjects) / pre-second dose of rMenB+OMV NZ (naïve subjects). Percentage of subjects with four-fold rise in hSBA titers relative to baseline were defined as: • for a pre-vaccination titer &lt; 4, a post-vaccination titer of at least 16; • for a pre-vaccination titer ≥ 4 but &lt;LLOQ, a post vaccination titer of at least fourfold the LLOQ; • for a pre-vaccination titer ≥LLOQ, a post vaccination titer of at least fourfold the pre-vaccination titer.</description>
        <time_frame>Group 3B: at 3, 7 and 30 days after third dose booster; Group B_0_1: at 3 (group B_0_1_1 only), 7 (group B_0_1_2 only) and 30 days post second dose</time_frame>
        <population>Analysis was performed on PPS kinetics which included all subjects who had no protocol deviations/any other reason defined prior to analysis, leading to exclusion &amp; correctly received the vaccination at day 1/day 31 &amp; day 1 &amp; provided evaluable immunogenicity result at all of days 4, 8 &amp; 31 (follow-on subjects)or at all of days 34/38 &amp; 61(naive)</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3B (V72_41)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1-month schedule in study V72_41 (NCT0142384) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72_41, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O2">
            <title>Group 3B (V72P10)</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0,1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during study V72P10, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O3">
            <title>Group 3B</title>
            <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 or 0,2 or 0,6 month schedule in study V72P10 (NCT00661713) and at 0,1 month schedule in study V72_41(NCT0142384), and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
          </group>
          <group group_id="O4">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O5">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O6">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With at Least Four-fold Increase in hSBA Titers Pre-booster/Second Dose Vaccination- Compared to 3, 7 and 30 Days Post- Booster/Second Vaccination</title>
          <description>The percentage of subjects with 4-fold rise at 3, 7, 30 days post-vaccination with a booster dose (follow-on subjects) /second dose (naive subjects) of rMenB+OMV NZ with respect to day 1 (follow-on subjects) / pre-second dose of rMenB+OMV NZ (naïve subjects). Percentage of subjects with four-fold rise in hSBA titers relative to baseline were defined as: • for a pre-vaccination titer &lt; 4, a post-vaccination titer of at least 16; • for a pre-vaccination titer ≥ 4 but &lt;LLOQ, a post vaccination titer of at least fourfold the LLOQ; • for a pre-vaccination titer ≥LLOQ, a post vaccination titer of at least fourfold the pre-vaccination titer.</description>
          <population>Analysis was performed on PPS kinetics which included all subjects who had no protocol deviations/any other reason defined prior to analysis, leading to exclusion &amp; correctly received the vaccination at day 1/day 31 &amp; day 1 &amp; provided evaluable immunogenicity result at all of days 4, 8 &amp; 31 (follow-on subjects)or at all of days 34/38 &amp; 61(naive)</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="242"/>
                <count group_id="O4" value="94"/>
                <count group_id="O5" value="109"/>
                <count group_id="O6" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 3 days post vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="242"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.48" upper_limit="6.6"/>
                    <measurement group_id="O2" value="2" lower_limit="0.22" upper_limit="6.3"/>
                    <measurement group_id="O3" value="2" lower_limit="0.7" upper_limit="4.8"/>
                    <measurement group_id="O4" value="6" lower_limit="1.3" upper_limit="16.5"/>
                    <measurement group_id="O5" value="2" lower_limit="0.05" upper_limit="9.7"/>
                    <measurement group_id="O6" value="4" lower_limit="1.0" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 - 7 days post-vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="242"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="82.6" upper_limit="94.0"/>
                    <measurement group_id="O2" value="86" lower_limit="77.8" upper_limit="91.6"/>
                    <measurement group_id="O3" value="88" lower_limit="82.8" upper_limit="91.5"/>
                    <measurement group_id="O4" value="45" lower_limit="30.4" upper_limit="61.2"/>
                    <measurement group_id="O5" value="26" lower_limit="15.0" upper_limit="39.7"/>
                    <measurement group_id="O6" value="35" lower_limit="25.4" upper_limit="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 - 1 month post-vacc.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="242"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="89.2" upper_limit="97.8"/>
                    <measurement group_id="O2" value="98" lower_limit="93.7" upper_limit="99.78"/>
                    <measurement group_id="O3" value="96" lower_limit="93.1" upper_limit="98.3"/>
                    <measurement group_id="O4" value="51" lower_limit="40.5" upper_limit="61.5"/>
                    <measurement group_id="O5" value="28" lower_limit="19.4" upper_limit="36.9"/>
                    <measurement group_id="O6" value="38" lower_limit="31.7" upper_limit="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99- 3 days post-vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="175"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="2.9" upper_limit="13.9"/>
                    <measurement group_id="O2" value="1" lower_limit="0.03" upper_limit="7.2"/>
                    <measurement group_id="O3" value="5" lower_limit="2.0" upper_limit="8.8"/>
                    <measurement group_id="O4" value="5" lower_limit="0.6" upper_limit="15.5"/>
                    <measurement group_id="O5" value="8" lower_limit="1.6" upper_limit="20.9"/>
                    <measurement group_id="O6" value="6" lower_limit="2.0" upper_limit="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99- 7 days post-vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="175"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="93.0" upper_limit="99.76"/>
                    <measurement group_id="O2" value="95" lower_limit="86.9" upper_limit="98.5"/>
                    <measurement group_id="O3" value="97" lower_limit="92.7" upper_limit="98.7"/>
                    <measurement group_id="O4" value="55" lower_limit="38.3" upper_limit="71.4"/>
                    <measurement group_id="O5" value="63" lower_limit="47.4" upper_limit="76.0"/>
                    <measurement group_id="O6" value="59" lower_limit="48.2" upper_limit="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99- 1 month post-vacc.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="175"/>
                    <count group_id="O4" value="82"/>
                    <count group_id="O5" value="87"/>
                    <count group_id="O6" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="93.0" upper_limit="99.76"/>
                    <measurement group_id="O2" value="96" lower_limit="88.8" upper_limit="99.2"/>
                    <measurement group_id="O3" value="97" lower_limit="93.5" upper_limit="99.1"/>
                    <measurement group_id="O4" value="56" lower_limit="44.7" upper_limit="67.0"/>
                    <measurement group_id="O5" value="72" lower_limit="61.8" upper_limit="81.5"/>
                    <measurement group_id="O6" value="64" lower_limit="56.8" upper_limit="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254- 3 days post-vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="231"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.48" upper_limit="6.6"/>
                    <measurement group_id="O2" value="2" lower_limit="0.24" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2" lower_limit="0.7" upper_limit="5.0"/>
                    <measurement group_id="O4" value="2" lower_limit="0.05" upper_limit="10.6"/>
                    <measurement group_id="O5" value="2" lower_limit="0.05" upper_limit="9.9"/>
                    <measurement group_id="O6" value="2" lower_limit="0.23" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254- 7 days post-vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="231"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="45.7" upper_limit="63.4"/>
                    <measurement group_id="O2" value="55" lower_limit="45.2" upper_limit="65.3"/>
                    <measurement group_id="O3" value="55" lower_limit="48.3" upper_limit="61.5"/>
                    <measurement group_id="O4" value="26" lower_limit="13.5" upper_limit="41.2"/>
                    <measurement group_id="O5" value="13" lower_limit="5.4" upper_limit="24.9"/>
                    <measurement group_id="O6" value="19" lower_limit="11.4" upper_limit="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254- 1 month post-vacc.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="231"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="108"/>
                    <count group_id="O6" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="73.8" upper_limit="87.8"/>
                    <measurement group_id="O2" value="80" lower_limit="71.1" upper_limit="87.5"/>
                    <measurement group_id="O3" value="81" lower_limit="75.3" upper_limit="85.8"/>
                    <measurement group_id="O4" value="35" lower_limit="25.8" upper_limit="46.1"/>
                    <measurement group_id="O5" value="20" lower_limit="13.2" upper_limit="29.2"/>
                    <measurement group_id="O6" value="27" lower_limit="21.3" upper_limit="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713- 3 days post-vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="240"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.49" upper_limit="6.7"/>
                    <measurement group_id="O2" value="3" lower_limit="0.6" upper_limit="7.6"/>
                    <measurement group_id="O3" value="3" lower_limit="0.9" upper_limit="5.4"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713- 7 days post-vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="240"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="30.6" upper_limit="48.1"/>
                    <measurement group_id="O2" value="28" lower_limit="19.6" upper_limit="36.9"/>
                    <measurement group_id="O3" value="34" lower_limit="27.8" upper_limit="40.1"/>
                    <measurement group_id="O4" value="14" lower_limit="5.3" upper_limit="27.9"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O6" value="6" lower_limit="2.3" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713- 1 month post-vacc.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="240"/>
                    <count group_id="O4" value="93"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="202"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="39.5" upper_limit="57.4"/>
                    <measurement group_id="O2" value="49" lower_limit="39.5" upper_limit="58.7"/>
                    <measurement group_id="O3" value="49" lower_limit="42.3" upper_limit="55.3"/>
                    <measurement group_id="O4" value="12" lower_limit="6.1" upper_limit="20.2"/>
                    <measurement group_id="O5" value="7" lower_limit="3.2" upper_limit="14.0"/>
                    <measurement group_id="O6" value="9" lower_limit="5.8" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>3 Days Post Booster/Second Vaccination. Four-fold Increase (Group 3B vs. Group B_0_1) Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.5</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>7 Days Post Booster/Second Vaccination. Four-fold Increase (Group 3B vs. Group B_0_1) Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>42.1</ci_lower_limit>
            <ci_upper_limit>62.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 Month Post Booster/Second Vaccination. Four-fold Increase (Group 3B vs. Group B_0_1) Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>50.5</ci_lower_limit>
            <ci_upper_limit>64.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>3 Days Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72_41) vs. Group B_0_1 (V72_41)] Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.1</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>7 Days Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72_41) vs. Group B_0_1 (V72_41)] Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>28.1</ci_lower_limit>
            <ci_upper_limit>58.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72_41) vs. Group B_0_1 (V72_41)] Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>32.7</ci_lower_limit>
            <ci_upper_limit>54.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>3 Days Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72P10) vs. Group B_0_1 (V72P10)] Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.0</ci_lower_limit>
            <ci_upper_limit>4.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>7 Days Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72P10) vs. Group B_0_1 (V72P10)] Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>45.0</ci_lower_limit>
            <ci_upper_limit>71.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain H44/76 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72P10) vs. Group B_0_1 (V72P10)] Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>61.2</ci_lower_limit>
            <ci_upper_limit>78.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>3 Days Post Booster/Second Vaccination. Four-fold Increase (Group 3B vs. Group B_0_1) Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>7 Days Post Booster/Second Vaccination. Four-fold Increase (Group 3B vs. Group B_0_1) Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.0</ci_lower_limit>
            <ci_upper_limit>48.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 Month Post Booster/Second Vaccination. Four-fold Increase (Group 3B vs. Group B_0_1) Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.2</ci_lower_limit>
            <ci_upper_limit>40.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>3 Days Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72_41) vs. Group B_0_1 (V72_41)] Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.7</ci_lower_limit>
            <ci_upper_limit>10.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>7 Days Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72_41) vs. Group B_0_1 (V72_41)] Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.7</ci_lower_limit>
            <ci_upper_limit>58.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72_41) vs. Group B_0_1 (V72_41)] Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31.1</ci_lower_limit>
            <ci_upper_limit>53.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>3 Days Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72P10) vs. Group B_0_1 (V72P10)] Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.2</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>7 Days Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72P10) vs. Group B_0_1 (V72P10)] Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.2</ci_lower_limit>
            <ci_upper_limit>47.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain 5/99 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72P10) vs. Group B_0_1 (V72P10)] Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.2</ci_lower_limit>
            <ci_upper_limit>34.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>3 Days Post Booster/Second Vaccination. Four-fold Increase (Group 3B vs. Group B_0_1) Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>7 Days Post Booster/Second Vaccination. Four-fold Increase (Group 3B vs. Group B_0_1) Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.6</ci_lower_limit>
            <ci_upper_limit>45.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 Month Post Booster/Second Vaccination. Four-fold Increase (Group 3B vs. Group B_0_1) Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>45.2</ci_lower_limit>
            <ci_upper_limit>61.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>3 Days Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72_41) vs. Group B_0_1 (V72_41)] Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.4</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>7 Days Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72_41) vs. Group B_0_1 (V72_41)] Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.1</ci_lower_limit>
            <ci_upper_limit>43.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/154 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72_41) vs. Group B_0_1 (V72_41)] Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>33.6</ci_lower_limit>
            <ci_upper_limit>57.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>3 Days Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72P10) vs. Group B_0_1 (V72P10)] Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.0</ci_lower_limit>
            <ci_upper_limit>5.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>7 Days Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72P10) vs. Group B_0_1 (V72P10)] Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.8</ci_lower_limit>
            <ci_upper_limit>54.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain NZ98/254 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72P10) vs. Group B_0_1 (V72P10)] Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>47.9</ci_lower_limit>
            <ci_upper_limit>69.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>3 Days Post Booster/Second Vaccination. Four-fold Increase (Group 3B vs. Group B_0_1) Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>5.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>7 Days Post Booster/Second Vaccination. Four-fold Increase (Group 3B vs. Group B_0_1) Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.1</ci_lower_limit>
            <ci_upper_limit>34.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 Month Post Booster/Second Vaccination. Four-fold Increase (Group 3B vs. Group B_0_1) Difference</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31.6</ci_lower_limit>
            <ci_upper_limit>46.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>3 Days Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72_41) vs. Group B_0_1 (V72_41)] Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.9</ci_lower_limit>
            <ci_upper_limit>6.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>7 Days Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72_41) vs. Group B_0_1 (V72_41)] Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.7</ci_lower_limit>
            <ci_upper_limit>37.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72_41) vs. Group B_0_1 (V72_41)] Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.1</ci_lower_limit>
            <ci_upper_limit>47.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>3 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>3 Days Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72P10) vs. Group B_0_1 (V72P10)] Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>7.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>7 days post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>7 Days Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72P10) vs. Group B_0_1 (V72P10)] Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.2</ci_lower_limit>
            <ci_upper_limit>36.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>1 month post vaccination-The group difference in percentages of subjects with response against N. meningitidis serogroup B indicator strain M10713 and the associated confidence interval for the difference was calculated using the method of Miettinen and Nurminen</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1 month Post Booster/Second Vaccination. Four-fold Increase [Group 3B (V72P10) vs. Group B_0_1 (V72P10)] Difference</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31.0</ci_lower_limit>
            <ci_upper_limit>51.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA ≥1:5 After Second Vaccination of rMenB+OMV NZ</title>
        <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713. Only subjects receiving a second vaccination (group B_0_1) were assessed for this outcome measure.</description>
        <time_frame>At Day 61 (30 days post second dose of vaccination.)</time_frame>
        <population>Analysis was performed on the PPS( per protocol set) catch up. The PPS catch up included all subjects who were randomized to group B_0_1 who correctly received two vaccinations at day 1 and day 31 &amp; provided evaluable immunogenicity result at day 61 for atleast one indicator strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O2">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O3">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥1:5 After Second Vaccination of rMenB+OMV NZ</title>
          <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713. Only subjects receiving a second vaccination (group B_0_1) were assessed for this outcome measure.</description>
          <population>Analysis was performed on the PPS( per protocol set) catch up. The PPS catch up included all subjects who were randomized to group B_0_1 who correctly received two vaccinations at day 1 and day 31 &amp; provided evaluable immunogenicity result at day 61 for atleast one indicator strain.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="215"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94.4" upper_limit="99.97"/>
                    <measurement group_id="O2" value="99" lower_limit="95.3" upper_limit="99.98"/>
                    <measurement group_id="O3" value="99" lower_limit="96.7" upper_limit="99.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="97" lower_limit="91.8" upper_limit="99.4"/>
                    <measurement group_id="O3" value="98" lower_limit="95.6" upper_limit="99.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="215"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="68.0" upper_limit="85.4"/>
                    <measurement group_id="O2" value="76" lower_limit="67.3" upper_limit="83.5"/>
                    <measurement group_id="O3" value="77" lower_limit="70.5" upper_limit="82.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="116"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="82.0" upper_limit="95.0"/>
                    <measurement group_id="O2" value="96" lower_limit="90.2" upper_limit="98.6"/>
                    <measurement group_id="O3" value="93" lower_limit="88.7" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA ≥1:8 After Second Vaccination of rMenB+OMV NZ.</title>
        <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.
Only subjects receiving a second vaccination (group B_0_1) were assessed for this outcome measure.</description>
        <time_frame>At Day 61 (30 days post second vaccination)</time_frame>
        <population>Analysis was performed on the PPS( per protocol set) catch up. The PPS catch up included all subjects who were randomized to group B_0_1 who correctly received two vaccinations at day 1 and day 31 &amp; provided evaluable immunogenicity result at day 61 for atleast one indicator strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O2">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O3">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥1:8 After Second Vaccination of rMenB+OMV NZ.</title>
          <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.
Only subjects receiving a second vaccination (group B_0_1) were assessed for this outcome measure.</description>
          <population>Analysis was performed on the PPS( per protocol set) catch up. The PPS catch up included all subjects who were randomized to group B_0_1 who correctly received two vaccinations at day 1 and day 31 &amp; provided evaluable immunogenicity result at day 61 for atleast one indicator strain.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="215"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94.4" upper_limit="99.97"/>
                    <measurement group_id="O2" value="97" lower_limit="92.7" upper_limit="99.5"/>
                    <measurement group_id="O3" value="98" lower_limit="95.3" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="97" lower_limit="91.8" upper_limit="99.4"/>
                    <measurement group_id="O3" value="98" lower_limit="95.6" upper_limit="99.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="215"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="54.0" upper_limit="73.7"/>
                    <measurement group_id="O2" value="69" lower_limit="60.0" upper_limit="77.4"/>
                    <measurement group_id="O3" value="67" lower_limit="60.3" upper_limit="73.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="116"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="77.2" upper_limit="92.0"/>
                    <measurement group_id="O2" value="94" lower_limit="88.0" upper_limit="97.5"/>
                    <measurement group_id="O3" value="90" lower_limit="85.4" upper_limit="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA ≥1:16 After Second Vaccination of rMenB+OMV NZ.</title>
        <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.
Only subjects receiving a second vaccination (group B_0_1) were assessed for this outcome measure.</description>
        <time_frame>At Day 61 (30 days post second vaccination)</time_frame>
        <population>Analysis was performed on the PPS( per protocol set) catch up. The PPS catch up included all subjects who were randomized to group B_0_1 who correctly received two vaccinations at day 1 and day 31 &amp; provided evaluable immunogenicity result at day 61 for atleast one indicator strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O2">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O3">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥1:16 After Second Vaccination of rMenB+OMV NZ.</title>
          <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.
Only subjects receiving a second vaccination (group B_0_1) were assessed for this outcome measure.</description>
          <population>Analysis was performed on the PPS( per protocol set) catch up. The PPS catch up included all subjects who were randomized to group B_0_1 who correctly received two vaccinations at day 1 and day 31 &amp; provided evaluable immunogenicity result at day 61 for atleast one indicator strain.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="215"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="83.3" upper_limit="95.7"/>
                    <measurement group_id="O2" value="91" lower_limit="83.8" upper_limit="95.2"/>
                    <measurement group_id="O3" value="91" lower_limit="86.0" upper_limit="94.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.0" upper_limit="100"/>
                    <measurement group_id="O2" value="96" lower_limit="90.4" upper_limit="98.9"/>
                    <measurement group_id="O3" value="98" lower_limit="94.8" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="215"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="30.0" upper_limit="50.2"/>
                    <measurement group_id="O2" value="56" lower_limit="46.1" upper_limit="64.7"/>
                    <measurement group_id="O3" value="48" lower_limit="41.5" upper_limit="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="116"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="64.7" upper_limit="82.8"/>
                    <measurement group_id="O2" value="92" lower_limit="85.8" upper_limit="96.4"/>
                    <measurement group_id="O3" value="84" lower_limit="78.5" upper_limit="88.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA Geometric Mean Titers (GMTs) After Second Vaccination of rMenB+OMV NZ.</title>
        <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.
Only subjects receiving a second vaccination (group B_0_1) were assessed for this outcome measure.</description>
        <time_frame>At Day 1 &amp; Day 61 (30 days post second dose of vaccination)</time_frame>
        <population>Analysis was performed on the PPS( per protocol set) catch up. The PPS catch up included all subjects who were randomized to group B_0_1 who correctly received two vaccinations at day 1 and day 31 &amp; provided evaluable immunogenicity result at day 61 for atleast one indicator strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O2">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O3">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA Geometric Mean Titers (GMTs) After Second Vaccination of rMenB+OMV NZ.</title>
          <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.
Only subjects receiving a second vaccination (group B_0_1) were assessed for this outcome measure.</description>
          <population>Analysis was performed on the PPS( per protocol set) catch up. The PPS catch up included all subjects who were randomized to group B_0_1 who correctly received two vaccinations at day 1 and day 31 &amp; provided evaluable immunogenicity result at day 61 for atleast one indicator strain.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="215"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" lower_limit="1.00" upper_limit="1.17"/>
                    <measurement group_id="O2" value="1.56" lower_limit="1.29" upper_limit="1.89"/>
                    <measurement group_id="O3" value="1.32" lower_limit="1.18" upper_limit="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 1 month post 2nd vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="215"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="47" upper_limit="68"/>
                    <measurement group_id="O2" value="64" lower_limit="53" upper_limit="78"/>
                    <measurement group_id="O3" value="61" lower_limit="53" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" lower_limit="1.03" upper_limit="1.35"/>
                    <measurement group_id="O2" value="2.18" lower_limit="1.58" upper_limit="3.00"/>
                    <measurement group_id="O3" value="1.63" lower_limit="1.35" upper_limit="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 1 month post 2nd vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239" lower_limit="200" upper_limit="285"/>
                    <measurement group_id="O2" value="274" lower_limit="207" upper_limit="363"/>
                    <measurement group_id="O3" value="257" lower_limit="217" upper_limit="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="115"/>
                    <count group_id="O3" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.58" lower_limit="1.30" upper_limit="1.91"/>
                    <measurement group_id="O3" value="1.28" lower_limit="1.15" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 1 month post 2nd vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="215"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="8.41" upper_limit="14"/>
                    <measurement group_id="O2" value="18" lower_limit="13" upper_limit="24"/>
                    <measurement group_id="O3" value="14" lower_limit="11" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="116"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="7.13" upper_limit="15"/>
                    <measurement group_id="O2" value="19" lower_limit="14" upper_limit="26"/>
                    <measurement group_id="O3" value="14" lower_limit="11" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 1 month post 2nd vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="116"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="25" upper_limit="44"/>
                    <measurement group_id="O2" value="60" lower_limit="48" upper_limit="75"/>
                    <measurement group_id="O3" value="46" lower_limit="38" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratio (GMRs) of GMTs One Month Post Second Vaccination Versus Pre Vaccination at Day 1</title>
        <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.
Only subjects receiving a second vaccination (group B_0_1) were assessed for this outcome measure.</description>
        <time_frame>At Day 1 &amp; Day 61 (30 days post 2nd vaccination)</time_frame>
        <population>Analysis was performed on the PPS( per protocol set) catch up. The PPS catch up included all subjects who were randomized to group B_0_1 who correctly received two vaccinations at day 1 and day 31 &amp; provided evaluable immunogenicity result at day 61 for atleast one indicator strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O2">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O3">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio (GMRs) of GMTs One Month Post Second Vaccination Versus Pre Vaccination at Day 1</title>
          <description>Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.
Only subjects receiving a second vaccination (group B_0_1) were assessed for this outcome measure.</description>
          <population>Analysis was performed on the PPS( per protocol set) catch up. The PPS catch up included all subjects who were randomized to group B_0_1 who correctly received two vaccinations at day 1 and day 31 &amp; provided evaluable immunogenicity result at day 61 for atleast one indicator strain.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="215"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="42" upper_limit="65"/>
                    <measurement group_id="O2" value="41" lower_limit="33" upper_limit="51"/>
                    <measurement group_id="O3" value="46" lower_limit="39" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204" lower_limit="162" upper_limit="257"/>
                    <measurement group_id="O2" value="123" lower_limit="74" upper_limit="204"/>
                    <measurement group_id="O3" value="156" lower_limit="117" upper_limit="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="115"/>
                    <count group_id="O3" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="8.41" upper_limit="14"/>
                    <measurement group_id="O2" value="11" lower_limit="7.94" upper_limit="16"/>
                    <measurement group_id="O3" value="11" lower_limit="8.88" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="116"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24" lower_limit="2.57" upper_limit="4.08"/>
                    <measurement group_id="O2" value="3.22" lower_limit="2.60" upper_limit="3.98"/>
                    <measurement group_id="O3" value="3.23" lower_limit="2.76" upper_limit="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With at Least Four-fold Increase in hSBA Titers at Pre-First Vaccination Compared to One Month Post-Second Vaccination</title>
        <description>The percentage of subjects with 4-fold rise at one month post-vaccination with a second dose (naïve subjects) of rMenB+OMV NZ with respect to day 1, to each and any one, two, three or all 4 indicator strains.
Percentage of subjects with four-fold rise in hSBA titers relative to baseline were defined as:
for a pre-vaccination titer &lt; 4, a post-vaccination titer of at least 16;
for a pre-vaccination titer ≥ 4 but &lt;LLOQ, a post vaccination titer of at least fourfold the LLOQ;
for a pre-vaccination titer ≥LLOQ, a post vaccination titer of at least fourfold the pre-vaccination titer.
Only subjects receiving the second dose of vaccination(group B_0_1) were considered for this outcome measure.</description>
        <time_frame>At Day 61 (30 days post second dose of vaccination)</time_frame>
        <population>Analysis was performed on the PPS( per protocol set) catch up. The PPS catch up included all subjects who were randomized to group B_0_1 who correctly received two vaccinations at day 1 and day 31 &amp; provided evaluable immunogenicity result at day 61 for atleast one indicator strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group B_0_1 (V72_41)</title>
            <description>Naive subjects from Australia and Canada, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O2">
            <title>Group B_0_1 (V72P10)</title>
            <description>Naive subjects from Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule in this study and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
          </group>
          <group group_id="O3">
            <title>Group B_0_1</title>
            <description>Naive subjects from Australia,Canada and Chile, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With at Least Four-fold Increase in hSBA Titers at Pre-First Vaccination Compared to One Month Post-Second Vaccination</title>
          <description>The percentage of subjects with 4-fold rise at one month post-vaccination with a second dose (naïve subjects) of rMenB+OMV NZ with respect to day 1, to each and any one, two, three or all 4 indicator strains.
Percentage of subjects with four-fold rise in hSBA titers relative to baseline were defined as:
for a pre-vaccination titer &lt; 4, a post-vaccination titer of at least 16;
for a pre-vaccination titer ≥ 4 but &lt;LLOQ, a post vaccination titer of at least fourfold the LLOQ;
for a pre-vaccination titer ≥LLOQ, a post vaccination titer of at least fourfold the pre-vaccination titer.
Only subjects receiving the second dose of vaccination(group B_0_1) were considered for this outcome measure.</description>
          <population>Analysis was performed on the PPS( per protocol set) catch up. The PPS catch up included all subjects who were randomized to group B_0_1 who correctly received two vaccinations at day 1 and day 31 &amp; provided evaluable immunogenicity result at day 61 for atleast one indicator strain.</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="215"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="91.3" upper_limit="99.4"/>
                    <measurement group_id="O2" value="94" lower_limit="88.1" upper_limit="97.6"/>
                    <measurement group_id="O3" value="95" lower_limit="91.6" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95.8" upper_limit="100"/>
                    <measurement group_id="O2" value="94" lower_limit="86.8" upper_limit="97.6"/>
                    <measurement group_id="O3" value="97" lower_limit="92.9" upper_limit="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="115"/>
                    <count group_id="O3" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="54.0" upper_limit="73.7"/>
                    <measurement group_id="O2" value="69" lower_limit="59.4" upper_limit="77.0"/>
                    <measurement group_id="O3" value="67" lower_limit="59.9" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="116"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="27.2" upper_limit="47.1"/>
                    <measurement group_id="O2" value="33" lower_limit="24.3" upper_limit="42.1"/>
                    <measurement group_id="O3" value="35" lower_limit="28.2" upper_limit="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited AEs were collected until 7 days after vaccinations. Unsolicited AEs were collected 30 days after each vaccination at day 31 (all subjects) and at day 61 (group B_0_1 subjects only).</time_frame>
      <desc>Serious Adverse Events (SAEs) were collected until study termination (1 month for group 3B subjects/ 2 months for group B_0_1 subjects)</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 3B</title>
          <description>Subjects who received two doses of rMenB+OMV NZ administered at 0, 1 month schedule in studies V72_41 or V72P10, and who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during parent studies, and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.</description>
        </group>
        <group group_id="E2">
          <title>Group B_0_1</title>
          <description>Naive subjects from V72_41 or V72P10 studies, who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="266" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="253" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injectioon site pain</sub_title>
                <counts group_id="E1" subjects_affected="259" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="251" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="150" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

